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Thesis Summary 
 
Today’s modern society is becoming constantly more dependent on the use of chemicals 
(ranging from industrial or pharmaceuticals products to pesticides and to personal care and 
household products) (Blaauboer, 2002a), which are a vital part of our daily life, and provide 
the society with a wide range of substantially high appreciated benefits, such as increased 
agricultural and industrial productivity. However, as a result of their manufacture, use or 
disposal, chemicals also have the potential to damage to the environment. Moreover, humans 
are exposed to a multitude of chemicals on a daily basis, both through their interaction with 
the environment and their specific use (Holmes, et al., 2010). Poisoning due to chemicals is 
generally recognized as a severe health problem and a very important public health issue. 
According to the Institute of Medicine (IOM), indeed, more than four million poisoning 
episodes occur annually in the United States (ICCVAM, 2006a; IOM, 2004), and poisonings 
result to be the second leading cause of injury-related deaths, exceeded only by car accidents 
(Birnbaum and Stokes, 2010). 
In order to ensure an adequate protection of human health and the environment, it is essential 
to evaluate if such products (chemicals, physical and biological agents) might cause adverse 
effects under normal and reasonably foreseeable use (Holmes, et al., 2010), and also to 
guarantee that reliable quality and adequate information on the adverse effects of exposure to 
such chemicals is provided (Blaauboer, 2002a). This process is named "risk assessment", and 
its principles are discussed in Chapter 1 in more details.  
Toxicological testing, which provides such information, is therefore an important part of the 
regulatory safety assessment for chemicals worldwide (Holmes, et al., 2010). Currently, test 
methods used to inform risk assessments on chemicals rely largely on animal models 
developed over the last 50 - 60 years. The latest available statistics on the use of animals in 
scientific procedures (European Commission, 2010a) show that in 2008 the number of 
animals employed in experimental and other scientific purposes, in all the 27 Member States 
of the European Union (EU), was just above twelve millions. Although the majority of these 
procedures were related to pharmaceutical development and efficacy studies, a significant 
proportion were associated with other toxicological purposes, including the safety assessment 
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of chemicals (Holmes, et al., 2010). However, the validity of the data obtained in these in 
vivo tests for the purpose of predicting the effects occurring in humans has been often 
questioned (Balls, 1991; Basketter, et al., 1997; Blaauboer, 2002a, 2002b; BUAV, 2001; 
Creton, et al., 2010; Frazier and Goldberg, 1990; Langley, 2005.; Worth and Balls, 2002; 
York, et al., 1996; York and Steiling, 1998). The reason for these criticisms is referred to the 
fact that any use of animals as a surrogate for humans involves a number of assumptions and 
extrapolations. In some instances, test animals are often exposed to higher doses than would 
be expected for typical human exposures, requiring specific assumptions related to effects at 
lower doses. Moreover, a wide range of variation in responses due to species differences was 
observed, and therefore it is virtually impossible to know whether results from rodents, for 
example, will provide an accurate prediction in humans. These scientific limitations, together 
with economic and ethical concerns (all of them analyzed more in details in Chapter 1) and 
legislative changes (among the others the very recent and of primary importance REACH 
Regulation, discussed in Chapter 2), are driving toxicologists to explore the potential of non-
animal alternative approaches to assess toxicity in the pharmaceutical and chemical industries 
(Holmes, et al., 2010). Recently indeed, many in vitro methods for toxicity testing have been 
developed as alternatives to whole animal tests, according to the 3Rs approach – Refinement, 
Reduction, and Replacement – started in 1959 by Russell and Burch (1959) (discussed more 
deeply in Chapter 1). Clearly, especially replacement and/or reduction of unnecessary in vivo 
tests, that today have reached a high priority level and have been heavily promoted (Hartung, 
2011), would have significant animal welfare benefits and would also result in lower testing 
costs and time (Creton, et al., 2010; Ukelis, et al., 2008). 
This research falls within the framework of the risk assessment of industrial/commercial 
chemicals, and specifically in the framework of the modern REACH Regulation, giving 
specific relevance to the 3Rs concept proposed by Russell and Burch (1959). The activity 
performed during the PhD, indeed, concerns the development of novel in vitro models in 
order to test the potential toxicity of drugs and chemicals, following two different lines of 
research, both of them based for the first time on the use of human Mesenchymal Stem Cells 
(MSCs) isolated from bone marrow. From our best knowledge indeed, both animal and 
human MSCs have never been adopted for developing in vitro model systems for acute 
toxicity tests, but their unique proprieties, such as unlimited proliferation ability, plasticity to 
generate others cell types and even being a more readily available sources of human cells, 
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clearly identify their potential benefits in toxicology (Davila, et al., 2004; Wobus and Loser, 
2011). Properties of MSCs and their primary importance in toxicology are discussed in 
Chapter 1.  
The first line of research, which resulted in a peer-review publication on In vitro Toxicology 
journal (Chapter 3), focused on the application of a selected in vitro toxicity method, the 
Neutral Red Uptake (NRU) assay, to detect chemical toxicity on human MSCs. Specifically, 
the aim of this study was to evaluate the applicability of human MSCs as cell line for in vitro 
cytotoxicity tests to correctly predict LD50 and the hazard category of chemicals according to 
the Globally Harmonized System of Classification and Labelling of Chemicals – GHS (ONU, 
2009). By comparing the behavior of human MSCs with the already validated 3T3 and NHK 
NRU test methods (validated by ICCVAM in 2006) (ICCVAM, 2006a, 2006b), the results 
clearly show that the tested cells can be confidently used to perform in vitro acute toxicity 
tests.  
The second line of research, on the contrary, was mainly focused on the research of new in 
vitro methods in order to test, specifically, the vascular toxicity of chemicals. This research is 
based on the application of emerging tissue engineering concepts on the field of toxicology. 
For the moment, only preliminary studies were conducted, which regarded the application of 
decellularization techniques to blood vessels harvested from animals at the local abattoir, in 
order to obtain biological scaffolds. These scaffolds could be subsequently used for 
recellularization processes using human MSCs, and setting up of perfused in vitro human 
toxicity tests. Of course this goal might be reached only if the animal vessel to be used as 
scaffold is completely acellular. The study presented in this thesis focused, therefore, on the 
histological evaluation of the different decellularization protocols performed and the obtained 
results allow one to conclude that an optimized effective protocol has been achieved using a 
combination of two different chemicals (ionic and non ionic detergents) and a physical 
treatment. 
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Chapter 1  
Overview of the Toxicological Risk 
assessment and Toxicity Testing 
 
1.1. Introduction 
As already introduced, modern society is increasingly depending on the use of chemicals 
produced for a wide variety of purposes, such as pharmaceuticals, personal care products, 
biocides, and so on. Moreover, their production and use may lead to many different adverse 
effects, both for humans and the environment. Recently, a systematic study of these risks has 
evolved in the direction of evaluating the balance between the benefits and the risk of adverse 
effects related to the use of chemicals, thus leading, in many cases, to the relatively safe use 
of chemicals in different sectors (Blaauboer, 2002a, 2002b). The process of assessment that 
aims to provide a scientific description of the risks of chemical exposures (Frazier and 
Goldberg, 1990), thus evaluating their potential impact on human health and welfare (Zurlo, 
et al., 1994), is named "risk assessment". 
Such process consists of both qualitative information on the nature of the outcome and 
quantitative assessment of the chemical hazard, exposure and magnitude of risks, and it 
combines predictions of toxic hazard with evaluations of likely exposure under specified 
conditions (Balls and Fentem, 1992). Specifically, the procedures used for this purpose are 
deeply rooted in the so-called "risk-assessment paradigm", which consists of different well-
defined elements: hazard identification, hazard characterisation, exposure assessment and risk 
characterisation (Blaauboer, 2002a, 2002b; Kroes and Feron, 1990). The hazard identification 
process involves the study of a chemical’s ability to cause adverse effects, and provide a 
quantitative description of the nature of these effects. The hazard characterisation, instead, 
provide a semi-quantitative evaluation of the nature of adverse effects (including, where 
possible, a dose-response assessment) (Blaauboer, 2002b; Holme and Dybing, 2002). 
Exposure assessment is again a semi-quantitative evaluation, but this time of the potential 
exposure to a chemical, both for human and the environment (Blaauboer, 2002b; Frazier and 
Goldberg, 1990). Information obtained from these three elements is then combined in a risk 
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characterization, which is a semi-quantitative estimation of the probability of occurrence and 
severity of adverse effects in a given population under defined exposure conditions 
(Blaauboer, 2002b). All these elements of the risk-assessment paradigm include a variety of 
experimental activities to be performed. While hazard identification and characterisation (in 
only one word hazard assessment) often depend on the use of animal experiments, exposure 
assessment is generally the result of chemical analysis, even if it might also depend on 
biomonitoring in animals or humans, and on computer-based estimations of exposure levels 
(Worth and Balls, 2002). 
In general, it is possible to say that toxicological evaluations currently form the basis of the 
assessment of risks from existing and new chemicals. Such evaluations rely mainly on the 
basis of tests conducted on laboratory animals, but these methods has been heavily criticised 
for many years, both for ethical, scientific and financial reasons (Balls, 1991; Basketter, et 
al., 1997; Blaauboer, 2002a, 2002b; BUAV, 2001; Creton, et al., 2010; Frazier and Goldberg, 
1990; Langley, 2005; Worth and Balls, 2002; York, et al., 1996; York and Steiling, 1998). 
The latter ones, together with legislative changes (REACH Regulation as last), are driving 
toxicologists to explore the potential of non-animal alternative approaches to assess toxicity 
in the pharmaceutical and chemical industries (Holmes, et al., 2010). 
 
1.2. Animal methods of toxicity testing  
Traditionally, as previously said, the toxic potential of industrial chemicals and household 
products was assessed by using animal models, and mammals (predominantly rodents) are 
often used as experimental animal species (Holmes, et al., 2010; Huggett, et al., 1996). 
 
1.2.1. A brief historical overview 
The use of animals in scientific research has a surprisingly long history, dating back to the 4th 
century BC (Before Christ). But it was from the 17th century, and even more during the 18th 
and 19th ones, that the use of animals in experimentation slowly became more common and 
accepted. Since then, indeed, animals have been repeatedly used through the history of 
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biomedical research, and it has to be noticed that many advances in this field could not have 
been made without the use of animals in some way, leading to enormous benefit to humanity 
(Cohen and Loew, 1984). With specific regard to toxicology testing, they became important 
in the 20th century, following the birth of the synthetic chemical industry in the late 1800s, 
when the need to understand how all the new substances might affect the health of workers 
and consumers involved in their production and use became more important. The field of 
toxicology, therefore, grew in response to these factors, and the use of whole animals was the 
most logical choice, because very few alternatives were available at that time. 
The use of living animals to study the potential adverse effects of new drugs, food additives, 
pesticides, and other substances effectively began during the 1920s, when a British 
pharmacologist, J.W. Trevan, proposed the so-called "lethal dose fifty percent" or "LD50" test 
(Trevan, 1927), which is a classic example of an exposure-response test and it is a measure of 
acute lethality (Eaton and Klaassen, 2001; Frazier, 1992). The principle of this test is to dose 
groups of animals (normally at least 5 animals) with a single dose of a test substance at 
concentrations expected to cause death in at least a fraction of the animals tested. Results of 
the test enable the calculation of the LD50 value, which is the dose that would kill 50% of the 
animals in the tested population within 14 days after a single exposure. The purpose was to 
standardize biological preparations, and then adapt them for testing the acute toxicity of 
chemical substances intended for human use (e.g. insulin) (Botham, 2002). This type of 
information has continuously provided an important basis for the safety assessment of 
chemical substances, and it is crucial essentially when considering accidental exposures at the 
workplace, at home (with specific regard to children) and following transport accidents as 
well (mainly for environmental assessments). 
Two decades after the introduction of the LD50 test, in 1944, the U.S. Food and Drug 
Administration (FDA) scientist John Draize developed standardized tests for eye and skin 
irritation (simply known as "Draize tests") using albino rabbits (Draize, et al., 1944). This 
paper became one of the most cited publications in toxicology, also providing the author with 
the 10th medal from the American Society of Cosmetic Chemists in 1957 for his work on 
product safety (Draize, 1958). Moreover, a few years later the development of the Draize test, 
the U.S. National Cancer Institute (NCI) developed a standardized test for the identification 
of chemical carcinogens through the daily dosing of rats and mice for long term experiments 
(up to two years) (Ward, 2007; Weisburger, 1983). Then, in the early 1960s, as a reaction to 
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the Thalidomide tragedy (Kim and Scialli, 2011), when thousands of babies worldwide were 
born with debilitating birth defects caused by the drug, a number of new and more complex 
studies on animals were developed (i.e. reproductive and developmental toxicity studies), in 
which a test agent is given to a large numbers of animals before they mate, throughout their 
pregnancy, and after giving birth, in order to evaluate effects on reproductive performance 
and/or developing offspring (Collins, 2006; Hendrickx and Binkerd, 1990; Koren et al., 1998; 
Stern, 1981; Tyl, 2010).  
Today, the use of living animals to study the potential adverse effects of new drugs, food 
additives, pesticides, and other substances cover a wide range of different endpoints that may 
be required by regulatory agencies/authorities. The main ones are: acute toxicity, skin 
irritation, eye irritation, corrosion, dermal sensitization, respiratory sensitization, chronic 
toxicity, mutagenicity, teratogenicity/embryotoxicity and carcinogenicity (Cote, et al., 1998). 
 
1.2.2. Aims and objectives of animal studies 
Animal-based studies have in general three major objectives: 
1. The identification of the major toxic effects of the considered substances by examining a 
multitude of potential target tissues; 
2. The identification of the toxic doses, both from single or repeated exposure; 
3. The determination of the level of intake that does not result in adverse effects (NOAEL). 
In order to achieve these aims, this kind of studies generally leads to observations of the 
clinical, histopathological and/or functional changes in the animals caused by the given dose 
of the considered chemical (Worth and Balls, 2002). The design, conduct and completeness 
of reporting of the experimental findings are of critical importance, in order to determine the 
validity and relevance of the results obtained from toxicological studies with mammalian 
species (IPCS, 1999). 
However, even if in many cases the performance of this kind of tests has lead to a relatively 
safe use of chemicals, the use of in vivo tests has often been questioned. This matter will be 
discussed in details in the subsequent paragraph. 
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1.3. Criticism to the use of animal methods 
The day-to-day practice of the procedures that rely on animal models in order to inform risk 
assessments on chemicals has, in many cases, led to the relatively safe use of chemicals in 
industry, or as agrochemicals, drugs, household chemicals or cosmetics. However, the use of 
in vivo tests for the purpose of predicting the effects occurring in humans has been often 
questioned, and there has been continuing intensive debate over thirty years (Balls, 1991; 
Basketter, et al., 1997.; Blaauboer, 2002a, 2002b; BUAV, 2001; Creton, et al., 2010; Frazier 
and Goldberg, 1990; Langley, 2005.; Worth and Balls, 2002; York, et al., 1996; York and 
Steiling, 1998). The reasons for these many criticisms are referred to ethical, scientific and 
also economic discussions and, as a consequence, many researches focus today on the way 
how these animal tests can be reduced, replaced or refined, accordingly to the 3Rs principle 
proposed by Russell and Burch (1959).  
In what follows, a brief explanations of all these matters, which led to numerous legislative 
changes during the course of history. 
 
1.3.1. Reasons for the criticism 
1.3.1.1. Scientific reasons  
The literature is full of unfortunate accidents where reliance on animal testing did not always 
correctly predict human toxicity (e.g. thalidomide) (Greenburg and Phillips, 2003; Kim and 
Scialli, 2011; Thorne, 2001), even if in most cases they led to a safe use of drugs and 
chemicals. As the famous NIH (National Institute of Health) pharmacologist Bernard Brodie 
said already in 1964: "… it is often a matter of pure luck that animal experiments lead to 
clinically useful drugs" (Hartung, 2008b). 
Scientific reasons against the use of animals rely mainly on the fact that using animals as a 
surrogate for predicting the biological activities of compounds in humans is always prone to 
some degree of uncertainty, and involves a number of assumptions and extrapolations, mainly 
due to species differences (Blaauboer, 2002a; Hartung, 2008b; Hartung, 2009; Holmes, et al., 
2010; Langley, 2005). It is indeed recognized that different species may respond differently 
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to the same substance (Ekwall, et al., 1998; Gold and Slone, 1993; Hurtt, et al., 2003). 
Differences in reactions to chemicals even between closely related species, such as rats and 
mice, which are more closely genotypically and phenotypically related to each other than 
they are to humans, demonstrate why toxicity tests on rodents have a dubious predictivity for 
humans (Hartung, 2008b; Hoffmann and Hartung, 2006). Even monkeys can differ 
considerably from humans, as experienced tragically in 2006 when the TeGenero anti-CD28 
antibody, after testing safe at 500-times higher concentrations in monkeys, led to multiple 
organ failure within hours in six human volunteers (Bhogal and Combes, 2006; Hartung, 
2008b). 
Important sources of uncertainty can be determined, for example, from differences in the 
mechanism of action of toxic compounds, or can be found in qualitative or quantitative 
differences between physiological and biochemical processes between species, and especially 
animals and humans. Parameters regarding the uptake, distribution, biotransformation and 
excretion may differ, resulting in some cases in dissimilarities in the concentration of a 
compound at the target tissue (Blaauboer, 2002a; Cohen, 2002, 2004; Haseman, et al., 1998; 
Robinson, et al., 2001; Schardein, 2000). 
Other difficulties arise from the fact that extrapolations have to be made from a rather small, 
but homogeneous, group of laboratory animals to the very heterogeneous human general 
population (Blaauboer, 2002a), therefore not considering pre-existing pathological 
conditions. The tested animals, which are usually inbred, specific pathogen-free and 
genetically homogeneous, therefore, do not represent normal animals of their species or the 
human population of concern.  
In concurring to such difficulties, there can be also problems in dosimetry (ACSH, 1997). 
Test animals are indeed often exposed to higher doses than would be expected for typical 
human exposures, requiring assumptions about effects at lower doses (Hartung, 2008b; 
Holmes, et al., 2010; Mehendale, 1995; Sumner and Stevens, 1994). That is because most 
small animals have short life spans and therefore can never be exposed to the chemicals as 
long as humans may be, and giving higher doses to them is an effort to maximize the 
sensitivity of the experiment, even if it has to be considered that, besides limiting costs and 
animal numbers (Hartung, 2009), many additional effects occur when extreme tissue 
concentrations are reached and defence systems are overwhelmed (Hartung, 2008b). 
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Moreover, traditionally, scaling up of doses has been used from small animals to larger 
humans, in order to adjust for metabolic differences in rates or sizes. However, available 
evidence shows that predicting the clearance of a chemical in humans on the basis of body 
weight ratios from animal tests does not give reliable results. Specifically, for drugs, that 
have several clinical trial results to confirm or contradict the animal test data, it is observed a 
more than 30% error rate; consequently, in the case of chemicals, for which there are seldom 
clinical trial results to be used, there is even less certainty (Hartung, 2008b; Langley, 2004; 
Mahmood and Balian, 1999). 
As a consequence of these factors, despite efforts to standardize procedures, the results of 
some animal tests can be highly variable and difficult to reproduce, which means there is a 
poor reliability (Bremer, et al., 2007; Gottmann, et al., 2001; Griffith, 1964; Weil and Scala, 
1971). Such a weak reproducibility can be due, indeed, to differences in strains and species, 
ages of animals used between the different laboratories, as well as the differences in weights 
and diet of the animal, for example. Other factors may include differences in technical ability 
of the investigators, as well as variations in ambient temperature, housing conditions of 
animals, humidity, noise and light/dark cycle as well (Balazs, et al., 1972; Dieke and Richter, 
1945). All of these factors could significantly affect the results (Langley, 2005), and for these 
reasons animal-based models had been heavily criticized from the scientific point of view. 
 
1.3.1.2. Economic reasons 
The financial and economic feasibility of toxicity testing using conventional whole animals is 
another aspect that needed to be re-evaluated, being indeed very time-consuming and 
expensive (Blaauboer, 2002a; Zurlo, 1998). Indeed, in vivo toxicity tests generally take 
months or even years to be conducted and analyzed; for example, in the case of 
carcinogenicity studies, even 4 or 5 years are needed. On the other hand, what it is extremely 
costly is firstly the maintenance of an adequate animal number and also the employment of 
qualified staff that can amount even to a hundred thousand euros. As a consequence of 
course, the number of replicates and repetitions are typically limited, contributing to the poor 
reliability of the tests. Moreover, standard animal tests can be quite costly as well. A survey 
of testing costs in Europe (Fleischer, 2007) showed average costs of, for example, 1,200 
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euros for skin irritation, 1,350 euros for eye irritation, 50,000 euros for 28 days repeated-dose 
oral studies (even twice this for the inhalation route), 330,000 euros for a two-generation 
reproductive toxicity study or 780,000 euros for a rat carcinogenicity bioassay (Hartung, 
2008b; USEPA, 2004). Therefore, considering the average cost for a project and that about 
9,300 new projects involving animal tests are started annually in Europe, it is clear how 
animal testing represents an enormous market and business. A study performed by Prognos 
(Prognos, 2007) on behalf of the European Commission in the context of the revision of the 
Directive for the protection of laboratory animals (Directive 86/609/EEC) (Council Of The 
European Communities, 1986) has estimated that, in the EU, about 1,330 establishments 
(industry, contract research laboratories and universities) perform animal tests, with a 
turnover of about 3 billion euros per year (Hartung, 2008b). 
 
1.3.1.3. Ethical reasons 
Ethical concerns are to be considered as well while evaluating the use of animals for 
experimental purposes. Some conventional toxicity test methods consume indeed hundreds or 
even thousands of animals per substance examined (Cooper, et al., 2006; Doe, et al., 2006), 
and most of these tests cause many animals to experience serious pain and distress (Langley, 
2005). This is particularly true for animals used in acute toxicity studies, especially those 
included in the high dose groups of repeated-dose experiments. Repeated injections, for 
example, often induce considerable local pain, and animals sometimes struggle desperately to 
avoid another injection, and also topical administration of irritant and corrosive substances to 
the skin and mucous membranes is a painful procedure. Moreover, considerable suffering 
must be assumed to affect tested animals, also in terms of, for example, perforated 
gastrointestinal ulcers, myocardial infarctions, liver necrosis and muscle wasting, besides 
functional disturbance (Balls, 1991). Moreover, it has to be considered also the stress and 
anxiety to which animals are subjected. There are many causes of stress in animals: transport, 
insufficient time for them to accustom, cages without enrichment, handling, procedures 
during daytime on night-active species, changes in groups for randomization, too many male 
animals caged together, just to make some important examples (Hartung, 2008b; Wolfer, et 
al., 2004). But there are also a long series of physical symptoms that cause such stressful 
condition, and they may include tremors, convulsions, loss of balance, unsteady gait, or even 
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paralysis, weight loss, breathlessness, excessive salivation, intestinal distension, diarrhoea, 
nasal or anal bleeding or discharge, lethargy, but also in the end coma and death (Balls, 1991; 
Langley, 2005). 
For all these reasons, the number of animal protection groups throughout the world is 
considerably growing and have placed considerable opposition to the use of whole animals 
for product safety testing (Zurlo, 1998), which, as reported from some countries' statistics, 
accounts for up to 70% of the most painful procedures to which animals are subject for all 
experimental purposes.  
 
1.3.2. The 3RS principle 
As a consequence, all these scientific limitations, together with the economic and ethical 
concerns, are driving toxicologists to explore the potential of non-animal alternative 
approaches to assess toxicity in the pharmaceutical and chemical industries (Holmes, et al., 
2010). Recently indeed, many in vitro methods for toxicity testing have been developed as 
alternatives to whole animal tests according to the 3Rs approach started in 1959 by Russell 
and Burch (1959).  
The 3Rs principle refers to the concept of Refinement, Reduction, and Replacement, which 
were described by the authors as the major routes to achieve the principles of human 
experimental technique (Piersma, 2006), and are further defined as follows:  
"Refinement" is defined as any method that reduces or eliminates pain and distress in animals 
during experiments. It is not enough to simply administer analgesics or anesthesia to animals 
in pain, but it also includes the substitution of species lower on the evolutionary scale for 
species that are higher in phylogeny. For example, using rodents instead of primates or using 
zebra fish instead of rodents in order to obtain the same or more scientific information 
(Goldberg and Locke, 2004). 
"Reduction" is defined as any method that seeks to use fewer animals in an experimental 
protocol to obtain the same or similar information of scientific value, or use the same number 
of animals to obtain more scientifically valuable information (Goldberg and Locke, 2004; 
Robinson, 2005). Therefore, the number of animals used should be the minimum that is 
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consistent with the aims of the experiment (Zurlo, et al., 1996), which is extremely important. 
However, when thinking about ways to reduce the number of animals used, researchers also 
have to ensure that the design of their experiment is robust. If by reducing animal numbers, 
researchers end up with data that have no statistical significance, they have wasted animal 
lives, which would be unacceptable (Robinson, 2005). 
Finally, "replacement" is defined by the use of techniques that do not use living animals and 
replace an animal model with alternative methods (Goldberg and Locke, 2004). The range of 
replacement alternative methods and approaches includes the improved storage, exchange, 
and use of information about previous animal experiments to avoid unnecessary repetition of 
animal procedures; use of physical and chemical techniques and predictions based upon the 
physical and chemical properties of molecules; use of mathematical and computer models; 
use of organisms with limited sentience such as invertebrates, plants and microorganisms; use 
of in vitro methods including cell cultures, tissue slices, and perfused organs; and also the use 
of human studies, including use of human volunteers, postmarketing surveillance, and 
epidemiology (Robinson, 2005; Zurlo, et al., 1996). Replacement represents the ultimate goal 
of the principle, and although difficult, considerable progress on replacement has been made 
by scientists. In many areas of the biomedical sciences, indeed, in vitro methods are 
increasingly used as the methods of choice in place of animal studies, not because they 
provide precisely the same information, but because they offer the best scientific approach 
(Zurlo, et al., 1996). Such in vitro methods will be discussed in a subsequent paragraph.  
Interestingly, the principles outlined by Russell and Burch in 1959 received little attention 
until the resurgence of the animal welfare movement in the mid-1970s, when the "Universal 
Declaration of the Rights of Animals" was promulgated (UNESCO, 1978), and today the 
concept of the 3Rs is very much in the forefront with regard to research, testing and 
education (Zurlo, 1998), and numerous legislative changes have been made as well in this 
sense. However, the greatest challenge for the 3Rs is perhaps the proposed new European 
Union legislation (referred to as REACH), which will require the safety testing of many 
already widely used household and industrial chemicals and new ones (Robinson, 2005). The 
entire Chapter 2 of this thesis work is dedicated to this legislation, to make clearer the matter 
from this point of view. 
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1.4. Alternative methods 
For all the reasons expressed in the previous paragraphs, since its establishment and during 
the subsequent half-century, the issue of the 3Rs and their application, to biotechnology in 
general and to toxicological research and testing more specifically, has continued to influence 
research and development of new methodologies and testing strategies, and tens of millions 
of dollars have been invested by corporations, governments, and other stakeholders with the 
goal of advancing in this field. The research focused, therefore, on the development of 
alternatives to animal experiments, that are defined as "procedures which can completely 
replace the need for animal experiments, reduce the numbers of animals required, or diminish 
the amount of pain or distress suffered by the animals in meeting the essential needs of 
humans and other animals" (Balls, 1991, 1994). Specifically, the development of in vitro 
systems, thought to be easier, more reliable, reproducible and predictive of some potential 
hazards in humans, and also considered to be less time consuming, more humane and cost 
efficient (Gad, 2000) than animal systems, became indispensable.  
Genetic toxicology was the first sub-discipline of toxicology in which in vitro test systems 
were used for toxicity testing to identify the mutagenic effects of compounds. An example of 
these tests could be the Ames Mutagenicity Assay with strains of Salmonella typhimurium 
(Ames, et al., 1973), which is dated back to the ‘70s. Anyway, the particular development of 
non-genotoxic in vitro toxicity studies for testing purposes did not begin to expand again until 
the mid 1980s, when in vitro tests have been proposed as a pre-screen or as an alternative 
method for endpoints such as prenatal toxicity, eye irritation, dermal irritation, tumour 
promotion and target organ toxicity (Atterwill, 1995; Frazier, 1992; Frazier and Goldberg, 
1990; Purchase, et al., 1998). At the beginning, in vitro tests were based only on empirical 
cell assays and they were merely descriptive, while today they are used extensively in 
academia, government and industry, and it is highly recognized that they involve for example 
mechanistically-based assays, translational toxicology (i.e., the use of in vitro data to predict 
human health consequences), and that there is the need for batteries of in vitro assays to 
determine the safety/hazard potential of a compound and to do risk assessment (Goldberg, 
2007). 
This kind of systems range from relatively simple subcellular fractions, tissue slices or 
perfused organ preparations, through primary cultures and cell lines – grown both as 
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monolayer cultures or suspension cultures and as monocultures or co-cultures – to three-
dimensional organotypic cultures, which include reconstructed tissue models. They can be 
used to evaluate both cytotoxicity and target organ toxicity, and each of these systems has its 
specific advantages and disadvantages, as reported by Bhogal et al. (2005) in Table 1.1 and 
briefly summarized in what follows. 
 
Table 1.1. The advantages and disadvantages of the various types of tissue culture systems 
used in in vitro toxicology. 
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1.4.1. In vitro tests for cytotoxicity 
The predictive value of in vitro cytotoxicity tests is based on the idea of "basal" cytotoxicity, 
a concept formalized by Ekwall (1983). Basal cell toxicity is defined as the adverse effect of 
such structures and functions that are essential for cell survival and proliferation (Seibert, et 
al., 1996). It is based on the fact that toxic chemicals affect the basic cell functions and 
structures, that are common to all cells (including integrity of membranes and cytoskeleton, 
cellular metabolism, cell division and so on), and that the toxicity can be measured by 
assessing the cellular damage. This interference with basal cell functions will in turn 
influence specific functions. 
A large number of in vitro test methods have been developed to assess a chemical’s cytotoxic 
potential (Zurlo, 1998), employing a wide variety of cell lines that can be isolated from many 
tissues and species, such as for example a wide range of murine and bovine cells, but also 
some human cell lines and primary cells (e.g. HL60 cells, HeLa, erythrocytes, hepatocytes, 
and so on) (Clemedson et al., 2000; Clothier et al., 1999; Fry et al., 1990; Hulme et al ,1987; 
Mancuso et al., 2010; Reader et al., 1989; Riddell et al., 1986a, 1986b; Spielmann et al., 
1999; Start et al., 1986; Worth and Balls, 2002). The introduction of the use of human cells, 
instead of animal ones, had the obvious advantage of avoiding the need for interspecies 
extrapolation (Combes, 2004) and therefore, today, the research is trying to focus mainly on 
them.  
 
1.4.1.1. General advantages and disadvantages 
Cell-based assays have several advantages, first of all the ease of performance and minimal 
or no animal use (Piersma, 2006; Zurlo, 1998), and the fact that a single organism can 
generate multiple cultures, which can be used also over extended periods of time and/or 
cryopreserved for future uses (Bhogal, et al., 2005; Brendler-Schwaab, et al., 1994). 
Moreover, these kinds of tests are more relevant and manageable than conventional 
laboratory animal models, and can provide several essential information about the potential 
effects of chemicals on specific cell properties, which can be studied both at molecular and 
cellular level (Bhogal, et al., 2005). That is a significant property even if, it has to be 
considered that projecting the effects of a chemical on a complex organism when the 
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observations are confined to a single type of cells in a dish is difficult, if not impossible. In 
addition, cell-based assays offer many advantages over in vivo studies, since they are 
generally less expensive and they also may be conducted under more controlled and 
automated conditions. These methods may be considered as both reduction alternatives (since 
many fewer animals are used compared to in vivo studies, despite the fact that small numbers 
of animals are still needed to obtain cells), and refinement alternatives (because they 
eliminate the need to subject the animals to the adverse toxic consequences imposed by in 
vivo experiments) (Zurlo, 1998). 
However, their relative simplicity is at the same time the major disadvantage of cell-based 
assay, because it does not represent the complexity of the entire organism, as already 
mentioned (Piersma, 2006; Zucco, et al., 2004). Indeed, the entire toxicological process 
consists of events that begin with the organism’s exposure to a physical or chemical agent, 
progress through cellular and molecular interactions and ultimately manifest themselves in 
the response of the whole organism. On the contrary, in vitro tests are generally limited to the 
part of the toxicological process that takes place at the cellular and molecular level (Zurlo, 
1998), and they allow the study of effects on single mechanisms only, e.g. cell proliferation 
[Pratt and Willis, 1985), cell adhesion (Braun, et al., 1979), metabolic cooperation (Trosko, et 
al., 1982), or cellular differentiation (Mummery, et al., 1984; Piersma, et al., 1993; Piersma, 
2006; Spielmann, et al., 1997). 
Furthermore, it is important to recognize that cells are finely balanced homeostatic machines 
that respond to external stimuli through complex pathways. Therefore, because toxicity could 
be the result of a multitude of cellular events (such as changes in cell morphology, 
differentiation, proliferation, function, excitability and/or communication), these in vitro 
systems - before being considered for risk assessment purposes - might require refinement 
(Bhogal, et al., 2005). For example, cell culture systems often lack essential systemic 
contributors to overall absorption, distribution, metabolism and excretion (ADME) (Bhogal, 
et al., 2005; Blaauboer, 2002a, 2002b; Flint, 1990), and also the complex interactions and 
effects of the immune, endocrine and nervous systems. One way to circumvent problems with 
metabolic competence is by adding subcellular or cellular metabolizing systems and 
assessing the production of known metabolites (Coecke, et al., 1999). This is particularly 
important, for example, when considering the elimination of lipophilic compounds, which is 
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crucially reliant on metabolism, that can generate toxic intermediates from innocuous parent 
chemicals (Bhogal, et al., 2005). 
Besides these limitations, it is important to be aware that also technical problems could also 
affect these tests. They include, among the others, the type of cells employed to study in vitro 
cytotoxicity, the solubility of the test chemicals studied, or the exposure period as well. 
Indeed, the contact time between cells and test chemicals, which is necessary to evaluate any 
delayed toxic potential of compounds, is not always sufficient (Blaauboer, 2002b). 
As a consequence of all these factors, difficulties in the interpretation and extrapolation of the 
results may arise as well, and it is therefore clear that the full potential of in vitro methods in 
toxicological risk assessment will need some additional considerations (Blaauboer, 2002b). In 
order to interpret the results of in vitro toxicity tests, to determine their potential usefulness in 
assessing toxicity and also to relate them to the overall toxicological process in vivo, it is 
firstly necessary to understand which part of the toxicological process is being examined. In 
an ideal situation, the mechanism of toxicity of each chemical would be known, such that the 
information obtained from in vitro tests could be fully interpreted and related to the response 
of the whole organism. However, this is virtually impossible, since relatively few complete 
toxicological mechanisms have been elucidated. Thus, toxicologists face with a situation in 
which the results of an in vitro test cannot be used as an entirely accurate prediction of in vivo 
toxicity because the mechanism is unknown. However, frequently during the process of 
developing an in vitro test, components of the cellular and molecular mechanisms of toxicity 
are elucidated, and therefore these kinds of tests are of fundamental importance and 
significance (Zurlo, 1998). 
 
1.4.1.2. Methods 
In these kinds of systems, the cells are generally exposed to a concentration range of the test 
compound for certain periods of time, in order to determine by direct exposure a critical 
concentration at a specific target site and specific toxic endpoint. Many in vitro models, 
which are based on either a colorimetric or bioluminescence reaction for example, have been 
developed and assays are currently available to measure the total number of cells, the number 
of dead or living one, or even the mechanism of cell death (e.g. apoptosis or necrosis), as well 
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as specialized function effects, such as for example contractility in the case of muscle cells, 
motility and velocity in the case of spermatozoa, glycogen content for hepatocytes, and many 
different others (Worth and Balls, 2002). Table 1.2, provided by Worth and Balls (2002), 
summarized both the types of cells and of endpoints used, and a brief overview of some of 
the most common cytotoxicity tests is reported in what follows. 
 
Table 1.2. An overview of in vitro assays for cytotoxicity/acute lethal toxicity.  
(LDH - lactate dehydrogenase; MDBK - Madin–Darby bovine kidney; NK - natural killer.) 
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Table 1.2. Continued 
 
 
 
One commonly used in vitro test for cytotoxicity is the Neutral Red Uptake (NRU) assay 
(Borenfreund and Puerner, 1985), which has been used also as method of choice in this thesis 
work (Scanu, et al., 2011). This method is based on the ability of viable cells to incorporate 
and bind Neutral Red (NR), which is a supravital dye that readily diffuses through the plasma 
membrane and concentrates in lysosomes of viable cells. For most applications, the assay is 
performed in a 96-well plate format, where each well can be used for a single determination, 
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making this arrangement suitable for multiple concentrations of the test chemical, as well as 
positive and negative controls, and for a sufficient number of replicates for each 
concentration. Following the treatment of the cells with various concentrations of the 
chemical, the cells are rinsed and treated with NR, which may be added upon removal of the 
chemical to determine immediate effects, or also at various times after the removal, in order 
to determine cumulative or delayed effects. The intensity of the colour in each well, measured 
by a spectrophotometer, corresponds to the number of living cells in that specific well (Zurlo, 
1998). What happens is that toxicants can alter the cell surface or the lysosomal membrane 
and cause fragility and other adverse changes that gradually become irreversible, causing cell 
death and/or inhibition of the cell growth. These effects cause a decrease of the amount of 
NR retained by the culture that is therefore directly proportional to the number of living cells. 
The NRU assay has an extended use among researchers, and it has been shown to be a 
reliable and sensitive assay for cell viability (Dierickx, 2000; Dierickx and Scheers, 2002; 
Eirheim, et al., 2004; Jirova, et al., 2003; Putnam, et al., 2002; Spielmann, et al., 1999). 
Recently, two proposed in vitro NRU assays using two different cell lines, mouse fibroblast 
(BALB/c) 3T3 cells and Normal Human Keratinocytes (NHK), have been validated by 
ICCVAM for predicting cytotoxicity in vitro (ICCVAM, 2006a, 2006b). 
Another relatively simple assay for cytotoxicity, based on a similar principle, is the MTT 
(3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) test, developed by Mosmann 
(1983). Tetrazolium salts (Smith, 1951) have been used for many years to distinguish living 
cells from dead ones, and this assay is based on a tetrazolium dye (MTT) that is reduced by 
mitochondrial enzymes to formazan granules of a blue colour. Only cells with viable 
mitochondria will retain the ability to carry out this reaction; therefore, the colour intensity is 
directly related to the degree of mitochondrial integrity, and it is a direct measure of the 
viability of the culture, with the advantages of rapidity and precision. This test is useful in 
order to detect general cytotoxic compounds, as well as those agents that specifically target 
mitochondria (Zurlo, 1998). 
Both of these methods are colorimetric ones and use the viability of the cells as major 
endpoint. Other similar tests, based on the same endpoint, could be, for example, the Lactate 
Dehydrogenase (LDH) test, that measure the integrity of the membrane by the activity of the 
cytoplasmic enzyme released by damaged cells (Decker and Lohmann-Matthes, 1988; 
Korzeniewski and Callewaert, 1983), or also the Adenosine Triphosphate (ATP) one, which 
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is a bioluminescence method that uses a specific enzyme (luciferase) in order to measure the 
concentration of ATP (present in all the metabolically active cells) (Crouch, 2000; Crouch, et 
al., 1993; Slater, 2001). 
Besides these, there are many new methods being developed also to detect cellular damage, 
and more sophisticated methods which employ fluorescent probes to measure a variety of 
intracellular parameters, such as calcium release and changes in pH and membrane potential. 
In general, these probes are very sensitive and may detect more fine cellular changes, thus 
reducing the need to use cell death as an endpoint (Worth and Balls, 2002; Zurlo, 1998). 
Once data have been collected on a series of chemicals using one of these tests, the relative 
toxicities may be determined and used to compare toxicities of different chemicals in vitro. 
This relative toxicity may be expressed as the concentration that exerts a 50% effect on the 
endpoint response of untreated cells, and can be referred to different values, such as the EC50 
(Effective Concentration for 50% of the cells) or the IC50 (Inhibitory Concentration, which is 
the concentration of a chemical that causes a 50% inhibition of a cellular process, e.g. the 
ability to take up NR). These data are then generally used in order to predict the toxicity in 
vivo, even if it is not easy to assess whether they are comparable to their relative in vivo 
toxicities, since there are so many confusing factors in the in vivo system, as already analyzed 
above in this Section. However, despite the numerous complexities and difficulties in 
extrapolating from in vitro to in vivo, these in vitro tests are proving to be very valuable, 
mainly because they are simple and inexpensive to perform, and also generally rapid and 
precise. They may be used as screens to flag highly toxic drugs or chemicals at early stages of 
development (Zurlo, 1998). 
 
1.4.2. Target organ toxicity 
Several in vitro tests have been developed in order to assess specific target organ toxicity as 
well, using cells or tissues from the organs that are typically target of toxicity (e.g. liver, 
kidney, lung, cardiovascular system, and so on) (Spielmann, et al., 1998). The detection of 
specific target organ and target organ system toxicity is, indeed, another important aspect of 
toxicological testing (Worth and Balls, 2002). As defined by Klaassen (2001), "most 
chemicals that produce systemic toxicity do not cause a similar degree of toxicity in all 
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organs, but usually produce the major toxicity to one or two organs. These are referred to as 
target organs of toxicity for that chemical." Table 1.3, provided by Worth and Balls (2002), 
summarize some of the available models in relation to three of the most important target 
toxicity: hepatotoxicity, nephrotoxicity, and neurotoxicity. 
 
Table 1.3. An overview of models for chronic toxicity testing. (ALAT - alanine 
aminotransferase; ASAT - aspartate aminotransferase; CYP - cytochrome P450; FACS - 
fluorescence-activated cell sorting). 
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Table 1.3. Continued 
 
 
 
1.4.2.1. General advantages and disadvantages 
These systems have several different advantages, depending on the type of system used, 
ranging from the retention of tissue- and organ-specific functions, biotransformation 
capability, and in some cases also retention of cell-to-cell and cell-to-matrix interactions and 
organotipic three-dimensional structures. 
However, there are also a number of difficulties associated with the design of such tests. The 
most notable one is the inability of maintaining many of the features of the organ in vivo. 
Frequently indeed, when cells are harvested from animals and placed into culture, they tend 
either to degenerate quickly and/or to dedifferentiate, which means they lose their organ-like 
functions and become more generic, with the consequence that within a short period of time, 
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usually a few days, the cultures are no longer useful for assessing organ-specific effects of a 
potentially toxic chemical. Moreover, even if it is possible to acquire much information about 
mechanisms of toxicity using one or more of these techniques, there is also in this case the 
difficulty of extrapolation from an in vitro system to the whole process occurring in vivo. 
Many of these problems are being overcome thanks to the recent advances in molecular and 
cellular biology, and all the new information obtained about the cellular environment in vivo 
may be utilized in modulating culture conditions in vitro. For example, many growth factors 
and cytokines are now commercially available and can be added to cells in culture, helping to 
preserve their integrity and to retain more differentiated functions for longer periods of time. 
Moreover, the knowledge of nutritional and hormonal requirements of cells in culture is 
increased, so that new media may be formulated (Zurlo, 1998).  
Recent advances have also been made in tissue engineering and identification of both natural 
and artificial extracellular matrices, which is important since culture of cells on them can 
have profound effects on both their structure and function. Therefore, and despite all the 
difficulties, these systems can provide great insight into organ-specific mechanisms of 
toxicity (Zurlo, 1998; Lavik and Langer, 2004). 
 
1.4.2.2. Methods 
Many target organ toxicity studies are conducted in primary cells, which are defined as cells 
that are freshly isolated from an organ, and that usually exhibit a finite lifetime in culture. 
Besides this, such cultures are very useful for studying specific cellular targets of a chemical 
and provide many advantages for toxicity assessment (Zurlo, 1998). The major one includes 
tissue-specific functions and retention of capacity for biotransformation. However, cellular 
isolation can result in damage to cell membrane integrity, with damage to or loss of 
membrane receptors and cellular products, even if fortunately, when forming monolayers, 
such cell damage is often repaired (Broadhead and Bottrill, 1997; Knight, 2008). 
Thanks to molecular biological tools, the development of continuous cell lines, that can be 
useful for target organ toxicity testing thus eliminating the need for freshly isolated cells, has 
been possible. These cell lines are generated by transfecting DNA (usually from a virus, e.g. 
adenovirus) into primary cells. Such DNA contains a gene or genes that, when expressed, 
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allow the cells to become immortalized, which means able to live and grow for extended 
(often indefinite) periods of time in culture (Knight, 2008; Zurlo, 1998). That is a clear 
advantage compared to the short life time of primary cells. Immortalization of cell lines, 
however, may significantly alter their characteristics and function (Luttun and Verfaillie, 
2006), therefore, before these cell lines may be used as a surrogate for a specific cell type, 
they must be carefully characterized to determine how "normal" they really are (Zurlo, 1998). 
The ability to generate immortalized cells, combined with the advances in cell culture 
technology, have greatly contributed to the creation of cell lines from many different species 
and organs, including rabbit kidney cells, mouse macrophages, rat hepatocytes, but also 
human lymphocytes, osteoblasts, and many others (Broadhead and Bottrill, 1997; Zurlo, 
1998). 
In recent years, tissue engineering has greatly facilitated the development of more-complex in 
vitro models than simple cell cultures (Lavik and Langer, 2004). In some instances, two or 
more cell types from an organ may be cultured together, and this provides an added 
advantage of being able to look at cell-to-cell interactions. It is possible to co-culture cells 
from the same, but also different organs, for example liver and kidney (Choucha-Snouber, et 
al., 2010), in order to assess the specific effects on kidney cells, of a chemical that must be 
bioactivated in the liver (Zurlo,1998). It is also now possible to grow stratified layers, each of 
them exhibiting morphological and functional differentiation, of epidermal cells. This has 
given rise to several commercially-available organotypic and reconstructed in vitro culture 
models, including EpiSkin® (http://www.loreal.com) and EpiDermTM 
(http://www.mattek.com), on which test protocols for skin corrosivity have been scientifically 
validated (Bhogal, et al., 2005; Botham, 2004; ICCVAM, 2002; OECD, 2004). Other 
organotypic models have also been developed, for example for ocular irritation (Zorn-
Kruppa, et al., 2004), neurotoxicology (Atterwill and Purcell, 1999), and respiratory toxicity 
as well (Bhogal, et al., 2005; Gray, et al., 1996). 
Of particular relevance to the development of many of these cell-based organotypic models is 
the use of substrates (Bhogal, et al., 2005), both natural and artificial extracellular matrices 
on which cells may be cultured, potentially having profound effects on both their structure 
and function, and thus providing great insight into organ-specific mechanisms of toxicity. 
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Other in vitro systems for studying target organ toxicity involve even more increasing 
complexity, and as they progress from single cells to whole organ cultures, they become more 
comparable to the in vivo situation, being very useful to assess interactions between multiple 
cell types. However, at the same time, they become much more difficult to control, because 
of an increased number of variables involved. Moreover, many of these systems can be used 
only in short-term studies, since they have limited in vitro longevities, which in turn limit 
their use (Zurlo, 1998).  
These progresses involve, for example, the availability of new instruments that enable the 
researcher to cut uniform tissue slices in a sterile environment. Precision-cut tissue slices are 
being used extensively for toxicological studies, and offer some advantage over cell culture 
systems mainly because all of the cell types of the organ are present and they maintain their 
in vivo architecture and both cell-to-cell and cell-to-matrix interactions (Zurlo, 1998). Indeed, 
organ slices represent a multicellular three-dimensional in vitro model, that possesses all the 
biologically relevant structural and functional features of in vivo tissues. Their potential for 
evaluating mechanisms of organ toxicity is due to the fact that all the various cell types 
within an organ will contribute to the biotransformation of a chemical, as well as to the 
release of a multitude of mediators which regulate the function of other cells. In the case of 
some chemicals, the primary target could be a minor cell population of the tissue, such as for 
example endothelial cells. Hence, the various cell types and the cell-to-cell and cell-to- 
matrix interactions become an important factor in the overall assessment of drug-induced 
effects and will enhance our ability to make better predictions of in vivo outcomes (Vickers 
and Fisher, 2004). The main disadvantage of these systems, as already mentioned, is the 
difficult in the maintenance of viability. Slices, indeed, degenerate rapidly after the first 24 
hours of culture, mainly due to poor diffusion of oxygen to the cells on the interior of the 
slices. However, different studies (Fisher, et al., 1995) have indicated that, by gentle rotation, 
it is possible to achieve a more efficient aeration allowing, together with the use of a more 
complex medium, the slices to survive for up to 72 hours. Moreover, advances continue to be 
made in obtaining higher quality tissues, and today the organ slice methodology is readily 
adaptable to various organs and species (including human), facilitating experimentation of 
cross-species comparisons (Bussek, et al., 2009; de Kanter, et al., 2002; Farkas and 
Tannenbaum, 2005; Liberati, et al., 2010; Parrish, et al., 1995). The application of human 
tissue to slice studies of course increases the utility of this model, and provides an important 
33 
 
bridge between animal derived data and the extrapolation to human outcome (Vickers and 
Fisher, 2004). 
Isolated perfused organs may also be used to assess target organ toxicity. Isolated organs 
represent three-dimensional biological system with a certain degree of retained physiological 
functions, native cellular architecture, and extracellular matrix that are superior to laboratory 
cell- and tissue-based bioassays. These systems are considered, for the above mentioned 
preservation of the three-dimensional organ structure, the closest model to the in vivo 
situation. They allow, indeed, for the maintenance of intra-organ interactions, and offer an 
advantage similar to tissue slices, since all cell types are present, but avoiding the stress to the 
tissue due to the manipulations involved in preparing slices. On the other hand, one of the 
major disadvantages is again their short-term viability, which limits their use for in vitro 
toxicity testing. Moreover, it has to be considered that, once extracted from the human body, 
an organ is instantly cut off from the original physiological environment in terms of blood 
supply, nervous modulation, immunoregulation, and thermo-homeostasis. Therefore, even if 
it is possible to set similar conditions for example in terms of body temperature and simulate 
the flow pattern due to normal heart beat and blood pressure, it is impossible to reproduce 
those dynamic regulatory changes due to nervous and immune regulation (Leung, 2009; 
Zurlo, 1998). 
In terms of serving as an alternative, these systems may be considered a refinement method, 
since the animals do not experience the adverse consequences of in vivo treatment with 
toxicants; however, at the same time, their use does not significantly decrease the numbers of 
animals required (Zurlo, 1998), and therefore they cannot be considered neither as reduction, 
nor as replacement alternatives. 
 
1.4.3. Use of stem cells in toxicology 
Special attention regarding in vitro toxicology has to be posed to models based on human 
Pluripotent Stem Cells (PSCs), that today are becoming an attractive alternative. Their recent 
application in toxicology and drug research, indeed, provide new alternative to the standard 
routine tests performed by industry and offer new strategies and benefits for chemical safety 
assessment (Laustriat et al., 2010; Trosko and Chang, 2010). The unique properties of PSCs, 
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such as unlimited proliferation ability without needing immortalization, plasticity to generate 
other cell types and more readily available and unlimited sources of human cells of well-
defined origin and homogeneous characteristics, clearly identified their benefits in toxicology 
(Davila et al., 2004; Wobus and Loser, 2011), showing significant advantages in comparison 
with somatic cells. To date, the attention of the scientific world focused mainly on Embryonic 
Stem Cells (ESCs), firstly established by Thomson et al., (1998), and on the more recently 
described induced Pluripotent Stem (iPS) cells, reprogrammed somatic cells firstly described 
by Yamanaka (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Their application 
studies, until now, regarded mainly embryo-, cardio-, and hepatotoxicity (Wobus and Loser, 
2011), but there is a wide expectations of future development of tests based on human PSCs-
derived keratinocytes (Guenou et al., 2009), fibroblasts (Cao et al., 2008), and also neural 
cells (Yla-Outinen et al., 2010; Zeng et al., 2006), that could significantly improve drug 
safety and drug development. 
With regard to embryotoxicity, several in vitro assays based on ESCs have been developed 
(Fraichard et al., 1995; Laschinski et al., 1991; Lim et al., 2009; Meamar et al., 2010; 
Rohwedel et al., 2001; Schmidt et al., 2001; Strubing et al., 1995; Wiese et al., 2011; Wobus 
et al., 1988, 1991, 1994), but the one developed by Spielmann and colleagues in 1997 
(Spielmann et al., 1997, 1998), the mouse Embryonic Stem Cell Test (mEST), is the only one 
that has been validated (Genschow et al., 2002). The mEST evaluate chemicals’ cytotoxicity 
and its inhibitory effect on the spontaneous differentiation of murine ESCs into functional 
contractile cardiomyocytes in embryoid bodies. Importantly, data obtained from the study 
were used to generate a prediction model for the distinction of chemicals in three classes: 
non, weakly or strongly embryotoxic chemicals (Genschow et al., 2002, 2004; Seiler et al., 
2006), predicting the embryotoxic potential of the tested compounds with a very high 
percentage of accuracy (about 78% for non and weakly embryotoxic compounds and 100% 
for strongly embryotoxic ones) (Genschow et al., 2002, 2004). However this test, even being 
the only well-established in vitro test for developmental toxicity based on mammalian cells 
(Bremer and Hartung, 2004), resulted to have several limitations (Piersma, 2004; Schmidt et 
al., 2001; Seiler et al., 2006). For example, it was laborious and time-consuming, and data on 
only the 20 chemicals used for the validation study were considered not sufficient to make 
final decisions on embryotoxicity. Moreover, there was the need for more reliable and 
reproducible differentiation procedures. Therefore, modifications and new endpoints were 
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recommended (Spielmann, 2009), such as the development of markers of neuronal, bone and 
cartilage in addition to cardiac ones, and also the inclusion of novel molecular endpoints in 
the future (Marx-Stoelting et al., 2009; Rohwedel et al., 2001; Spielmann, 2009). Such 
improvements would also be needed for the establishment of similar tests based on human 
ESCs, that would represent a significant progress, enhancing the predictivity of in vitro 
assays and avoiding problems associated with the interpretation of results from animal-based 
assays in a human context. Today, there are several recent studies (listed in Table 1.4 
provided by Wobus and Loser (2011) that started to demonstrate that human ESCs could be 
used as a suitable model for analysing developmental toxicity, but it is clear that several 
problems (similar to those expressed for murine cells) still need to be solved.  
The application of human iPS cells in embryotoxicity has been discussed (Heng et al., 2009) 
and considered as a promising tool as well, but future works are still needed to show if they 
can be applicable and if they may offer advantages over ESCs. 
ESCs have been widely used also in the field of cardio- and hepatotoxicity, for which they 
could have significant advantages over the in vitro and in vivo systems currently used. 
Indeed, since the first successful derivation of human ESCs-derived cardiomyocytes (Kehat 
et al., 2001), and the early studies where mouse ESCs differentiated resulting in the 
formation of hepatocytic cells expressing hepatocyte-specific genes (Lavon and Benvenisty, 
2005), a large number of studies has been published on the generation of cardiac myocytes or 
hepatocytes from ESCs and from iPS cells as well (Abe et al., 1996; Baxter et al., 2010; 
Beqqali et al., 2006; Burridge et al., 2007; Freund et al., 2010; Laflamme et al., 2007; Lavlon 
and Benvenisty, 2005; Liu et al., 2010; Mohr et al., 2010; Moore et al., 2008; Moretti et al., 
2010; Mummery et al., 2003; Pal and Khanna, 2007; Passier et al., 2005; Si-Tayeb et al., 
2010a, 2010b; Song et al., 2009; Sullivan et al., 2010; Touboul et al., 2010;Yokoo et al., 
2009; Zhang et al., 2009; Zwi et al., 2009). For a detailed review of the state of the art of 
these studies see Wobus and Loser (2011). 
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Table 1.4. Published developmental toxicology studies involving human ESCs and/or 
human ESC-derived cells. 
 
 
With regard to cardiac safety pharmacology, current preclinical models, both in vivo and in 
vitro, do not accurately predict clinical outcomes and present some limitations, mainly related 
to costs and sensitivity. Cultures of human cardiomyocytes are an excellent in vitro model 
system for safety evaluation (Bird et al., 2003), however the availability of primary cells 
from healthy donors is limited. As a consequence, the establishment of novel test systems to 
screen new chemicals and identify their safe use in humans is highly desirable (Davila et al., 
2004; Wobus and Loser, 2011). The potential of ESCs in safety toxicology and 
pharmacology has already been demonstrated by studies on murine cell lines (Boheler et al., 
2002; Wobus and Boheler, 2005), however only human cells could overcome inter-species 
limitations. The potential usefulness of human ESCs-derived cardiomyocytes was shown in 
several recent studies (Braam et al. 2010; Caspi et al. 2009; Jonsson et al. 2010; Liang et al. 
2010; Otsuji et al. 2010; Pekkanen-Mattila et al. 2010; Peng et al. 2010), even if information 
on their applicability to safety pharmacology is still restricted. The advantages of these cells 
are related mainly to the human origin and the fact that express characteristic cardiac-specific 
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genes, therefore avoiding species-specific differences inherent to animal-based test systems; 
moreover, they are able to respond to external stimuli and show the anticipated response to a 
broad range of pharmaceutically active substances. Furthermore, these cells are genetically 
identical and can be kept in culture for at least several weeks. For all these reasons, human 
PSC-derived cardiomyocytes represent a promising option and may offer the basis for the 
development of novel, human-specific platforms for assessing the safety of novel 
compounds, even if several problems still have to be solved in order to make them widely 
applicable to screening procedures and to gain the acceptance of regulatory authorities, such 
as, among the others, the establishment of more efficient and reproducible differentiation 
protocols for the production of mature cells at large numbers (Wobus and Loser, 2011). 
The knowledge obtained from progresses made on the differentiation of human ESCs into 
cardiomyocytes is now being applied to iPS cells as well (Freund et al., 2010; Moretti et al., 
2010; Yokoo et al., 2009; Zhang et al., 2009; Zwi et al., 2009), leading to consider these cells 
as a promising tool for toxicological studies and also attracting the interest of pharmaceutical 
industry. For example, the Madison-based company Cellular Dynamics International (CDI, 
www.cellulardynamics.com) has launched human iPS cells-derived iCell® Cardiomyocytes 
designed to aid drug discovery and improve the predictability of compound efficacy and 
toxicity (Cellular Dynamics, 2009). 
With regard to hepatotoxicity, the availability of primary cells from healthy donors is limited, 
because of the use of large numbers of human hepatocytes in the basic and clinical studies 
(Davila et al., 2004). Initial progresses have been made in the establishment of protocols for 
the generation of human PSCs-derived hepatocyte-like cells. However, until now, a validated 
standardized protocol for the differentiation is not available and there are only limited data 
available on long term cultivation of these cells; this is a critical factor for the implementation 
of novel human cell-based in vitro assays, since detection of drug effects might require the 
application over an extended period of time or repeated exposure. Results are anyway 
encouraging (Basma et al., 2009; Guguen-Guillouzo et al., 2010; Hay et al., 2008) and 
several advantages could rise from this kind of tests, for example they may have the potential 
to predict hepatotoxicity already in early phases of drug development, leading consequently 
to a reduction of costs and to improved safety profiles of drugs and chemicals. However, 
before such systems can be implemented into routine toxicity testing, also in this case some 
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problems still have to be solved, including again the development of robust and reproducible 
differentiation protocols (Wobus and Loser, 2011). 
We can conclude, therefore, that human PSCs offer enormous opportunities for the 
development of promising and innovative in vitro toxicological systems, providing a new tool 
for better understanding the mechanisms involved in drug-induced adverse reactions and to 
potentially predict and avoid toxicity in humans. However, the controversy surrounding the 
use of human ESCs (Vojnits and Bremer, 2010) has limited the development of these cells, 
and the research is now focusing especially on the use of different sources of cells, such as 
the iPS cells. At the same time, also iPS cells present some important limitations, such as the 
serious problem of presenting a potentially tumorigenic status. Therefore, further studies are 
highly required. The high interests in using stem cells in safety toxicology and pharmacology 
is illustrated by collaborative programmes between industries and research institutions 
(Baker, 2010; Caspi et al., 2009; Ebert and Svendsen, 2010; Sartipy et al., 2006; Trosko and 
Chang, 2010), such as the consortium Stem Cells for Safer Medicine (SC4SM) (Jha, 2007). 
 
1.5. Validation, regulatory acceptance and 
international organisation 
In order to facilitate the replacement of old in vivo toxicity tests with new in vitro 
alternatives, which is of extreme importance especially with regard to the issues addressed in 
this Thesis Chapter, national and international authorities have developed processes and 
criteria for evaluating and determining if a new toxicity test methods can replace an existing 
one. The major difficulty in this sense is represented by test method validation and regulatory 
acceptance, which will be briefly discussed in what follows.  
 
1.5.1. Validation authorities 
The several organisations that begun to pursue, form, and validate in vitro toxicity systems, 
are distributed all around the three main continents, and are represented by groups of 
companies, industry associations, animal welfare organisation, and national government and 
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international agencies (Balls and Fentem, 1999). Three of them are the main organisations 
that developed the validation criteria for new toxicological test methods in use today, 
working together in order to harmonize and avoiding major differences between them. They 
are the Organisation for Economic Cooperation and Development (OECD), the European 
Centre for the Validation of Alternative Methods (ECVAM), and the Interagency 
Coordinating Committee on the Validation of Alternative Methods (ICCVAM).  
 
1.5.1.1. ECVAM  
The EU was the first to establish a formal validation process by creating, in 1991, the 
European Centre for the Validation of Alternative Methods (ECVAM, http://ecvam.jrc.it/) 
(Commission of the European Communities, 1991b), which became operational in 1993 and 
was established, pursuant a requirement in Directive 86/609/EEC on the protection of 
laboratory animals (Council of the European Communities, 1986), in order to conduct 
research, develop non-animal methods, and implement validation studies. ECVAM, as a 
service of the EU Joint Research Centre (JRC), has pioneered the validation process (Zuang 
and Hartung, 2005), participating in early validation studies and international efforts to define 
validation principles for alternative test methods, and publishing recommendations 
concerning practical and logistical aspects in a workshop report of 1995 (Balls, et al., 1995). 
Current principles and procedures for validation have been published by Worth and Balls 
(2002) and also ECVAM Guidelines have been provided for the submission of a test method 
(http://ecvam.jrc.it/upload_docs/m_5/Guidelines.pdf). ECVAM has continuously worked 
with other organizations, such as ICCVAM or OECD, with the aim of having an early 
exchange of information on the validation of new methods, as to facilitate internationally 
harmonized validation and acceptance of alternative methods. 
 
1.5.1.2. ICCVAM  
The U.S. Government established in 1994 the Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM, http://iccvam.niehs.nih.gov/), with the aim of 
establishing a formal process by which in vitro methods would be validated and 
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recommended for regulatory acceptance. ICCVAM is an interagency committee composed of 
representatives from 15 U.S. Federal agencies, who in turn collaborate with the NTP 
(National Toxicology Program) Interagency Center for the Evaluation of Alternative 
Toxicological Methods (NICEATM), that provides administrative and technical support for 
the activities of ICCVAM. NICEATM-ICCVAM conduct rigorous reviews of both new or 
revised test methods, and coordinate issues on validation, acceptance, and national and 
international harmonization of toxicological test methods (Schechtman and Stokes, 2002). It 
places priority attention on those methods that may improve prediction of adverse human, 
animal or ecological effects, and those that may reduce, refine or replace animal use. 
ICCVAM published its original validation and regulatory acceptance criteria document in 
1997 (ICCVAM, 1997), and then a submissions guidance document has been developed 
(ICCVAM, 2003) to be used in conjunction with information in the 1997 document.  
 
1.5.1.3. OECD  
The Organisation for Economic Cooperation and Development (OECD, 
http://www.oecd.org/home/0,2987,en_2649_201185_1_1_1_1_1,00.html) is an inter-
governmental organization, established in 1961 and composed today of 30 different 
countries, whose general mission is to promote policies that will improve the economic and 
social well of people all around the world. The OECD started working on guidance for test 
method validation around 1994, when the international debate on test method validation was 
considerable, and with the aim of "internationally harmonize the various published and 
advocated concepts for the validation of alternative test methods" (OECD, 2002). The OECD 
validation and acceptance criteria have been refined over time, and the current guidance is the 
"OECD Guidance Document on the Validation and International Acceptance of New or 
Updated Test Methods for Hazard Assessment" (OECD, 2005). According to the OECD, a 
test method can be validated prior to being considered for an OECD Test Guideline (that is 
published only when consensus is reached between all members), but validation of a test is 
not a prerequisite for initiating the development of a Test Guideline.  
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1.5.1.4. OTHERS  
Other organizations are distributed all around the world. For example, in Europe, there are 
also several other organizations besides ECVAM, such as the Fund for the Replacement of 
Animals in Medical Experiments (FRAME, www.frame.org.uk), established in 1982, with 
the aim to develop and validate alternative in vitro test systems and with the ultimate goal of 
eliminating the need to use laboratory animals in any kind of medical or scientific procedure. 
In the U.S., it is important also the John Hopkins Centre for Alternatives to Animal Testing, 
(CAAT, www.caat.jhsph.edu), established to find new methods to replace the use of 
laboratory animals in experiments, reduce the number of animals tested, and refine necessary 
tests to eliminate pain and distress. There are also, among the others, the Netherlands Centre 
for Alternatives to Animal Use (NCA), established as a national information centre on 
alternatives in 1994; the European Consensus Platform on Alternatives (ECOPA), founded in 
2002 in Brussels by national platforms from 10 European states (i.e. Austria, Belgium, Czech 
Republic, Finland, Germany, Italy, Netherlands, Spain, Switzerland, and UK); and also the 
centre for the Documentation and Evaluation of Alternative Methods to Animal Experiments 
(ZEBET), established in Germany in 1989. Notable are also the Japanese Centre for the 
Validation of Alternative Methods (JaCVAM), as a part of the Japan's National Institute of 
Health Sciences (NIHS) and the recently established Korean Center for the Validation of 
Alternative Methods (KoCVAM), as a part of the National Institute of Food and Drug Safety 
(NIFDS) in the Korean Food and Drug Administration. Both JaCVAM and KoCVAM 
conducted validation studies and participated in international validation and harmonization 
activities.  
 
1.5.2. The validation process 
The implementation of these new in vitro systems in toxicological risk assessment, together 
with their regulatory acceptance, must be preceded by a detailed evaluation of their relevance 
and reliability, which means that it has to be previously performed a process, known as 
validation (Balls and Fentem, 1999; Balls and Karcher, 1995). 
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1.5.2.1. Definition 
The concept of validation was recognized as necessary for acceptance of an alternative 
method in the ‘80s, and since then the need to create a process that would codify validation 
arose. The concept was simple: once a test was validated, everyone would use it (Goldberg, 
2007). Validation was defined by the ECVAM as "the process by which the reliability and 
the relevance of a procedure are established for a specific purpose" (Balls, et al., 1995), 
definition that has been agreed at a workshop on the principles of the validation of toxicity 
test procedures, held in Switzerland in 1990 (Balls, et al., 1990a, 1990b), following a report 
on validation produced by Frazier (1990) for the OECD and the discussions at the 1987 
CAAT symposium on validation (Goldberg, 1988). The current criteria and principles have 
evolved from those established there, and very similar definitions were then proposed by 
OECD and ICCVAM (ICCVAM, 2003; OECD, 2005). 
From a scientific point of view the validation of any test procedure has a number of 
interesting aspects, which are also reflected in the above-cited definition. The "relevance" of 
a procedure refers to the scientific value and the practical usefulness of the results it provides 
(Balls and Fentem, 1999), for assessing whether the compound is a hazard or not (Goldberg 
and Locke, 2004). Its meaning was clarified in OECD Guidance Document No 34 (OECD, 
2005) as follows: "Description of relationship of the test to the effect of interest and whether 
it is meaningful and useful for a particular purpose. It is the extent to which the test correctly 
measures or predicts the biological effect of interest. Relevance incorporates consideration of 
the accuracy (concordance) of a test method."  
During the process of validation, "reliability" needs to be established as well, which means 
that all the procedures should be reproducible and meaningful, with an adequate predictive 
ability (Balls and Fentem, 1992). Such predictivity should be defined by comparison of in 
vitro results with existing in vivo data (Piersma, 2006), while reproducibility concerns with 
results within and between laboratories, and over time. In the official definition, reliability 
was used instead of reproducibility, because it implies that results are good (Balls and 
Fentem, 1999). The term reliability was also clarified in OECD Guidance Document No 34 
(OECD, 2005) as follows: "Measures of the extent that a test method can be performed 
reproducibly within and between laboratories over time, when performed using the same 
protocol. It is assessed by calculating intra- and inter-laboratory reproducibility and intra-
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laboratory repeatability." Relevance and reliability are off course strictly related, since a 
procedure that provide reliable but irrelevant results, or that provide relevant but unreliable 
results, is definitely of any utility (Balls and Fentem, 1999). 
Another crucial point is that the "purpose" needs to be clearly identified, since it covers the 
scope of the procedure and what can be expected of it. Essentially, it is the basis on which the 
validity of the method should be judged (Balls and Fentem, 1999; Barile, et al., 1994). 
Validation is therefore a process by which the credibility of a candidate test is established for 
a specific purpose (Balls and Fentem, 1999). More importantly, it is not a process to develop 
new approaches, optimize approaches, or compare one approach to another, but it is 
essentially a process which verifies that the method or procedure under investigation 
performs as intended (Wilcox and Goldberg, 2011). 
 
1.5.2.2. Steps of the process 
A formal validation study requires substantial organization and planning, involving an 
evaluation of the performance of the test with an optimized protocol and an optimized 
prediction model, as well as an independent analysis of data and outcome in relation to the 
predefined goal of the study (Balls and Fentem, 1999). Five main stages have been identified 
in the evolution of new test methods: test development, prevalidation, proper validation, 
independent assessment, and then progression toward regulatory acceptance (Balls, et al., 
1995; Wilcox and Goldberg, 2011). 
Before undertaking a validation study, it is necessary to properly develop the test satisfying a 
set of important criteria. That means it is necessary to identify the purpose and its practical 
applications, explain the basis of the test, define the protocol, operating procedures and also 
an adequate set of chemicals and adequate controls to be used, together with a specification 
of the endpoints and methods for calculating and expressing results. Moreover, as proposed 
by Bruner et al. (1996), the development of an appropriate prediction model is also necessary 
(Balls and Fentem, 1999; Worth and Balls, 2004). An explanation of the need for the method 
in relation to existing in vivo ones and other non-animal methods is also required in this phase 
of the process, as well as a statement about its limitations (Worth and Balls, 2004). 
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As suggested by Curren et al. (1995), soon after the development of the test, a prevalidation 
study is now formally required in order to improve the efficiency and speed of the validation 
process and maximize the successful results (Balls and Fentem, 1999; Goldberg and Locke, 
2004). It consists in a small scale inter-laboratory study, that provides the opportunity to 
optimize the test method protocol, therefore ensuring that an optimized protocol is available 
for further assessment in a formal validation study, and to obtain a preliminary assessment of 
its performance and reproducibility (Curren, et al., 1995). Moreover, it is performed to verify 
that the protocol is transferable to other laboratories, which is of primary importance for the 
concept of reliability (Balls and Fentem, 1999; Goldberg and Locke, 2004; Worth and Balls, 
2004). The prevalidation process is divided into three consecutive phases (Curren, et al., 
1995). During the so-called "method refinement" phase (phase I), the protocol and prediction 
model of a test method are refined in a single laboratory (that have previous experience in the 
use of the test), whereas during the "method transfer" phase (phase II), an assessment is made 
of the transfer ability of the method to a second laboratory, making any necessary 
refinements to the protocol and prediction model. During the "method performance" phase 
(phase III), finally, the relevance and reliability of the test are assessed under blind conditions 
in three or more laboratories (generally including the first two ones) (Worth and Balls, 2004). 
Preferably, some flexibility in methodology should be allowed, since it generally facilitates 
the introduction of a test system in a laboratory and when possible is a sign of robustness 
(Balls and Fentem, 1999; Piersma, 2006). 
Then, the formal larger inter-laboratory validation study, designed to obtain a more definitive 
assessment of relevance and reliability, can be performed. It can be considered as an extended 
version of the last phase of prevalidation, in which additional chemicals are tested under 
blind conditions (Worth and Balls, 2004). The key to a successful validation study is clarity 
of definition of goals, excellence of design and management, high quality of laboratory work 
and statistical analysis, and strength of partnership at many levels (Balls and Fentem, 1999). 
The validation studies are therefore obviously complex, expensive and time consuming. They 
should be performed in a series of reference laboratories, since both intra-laboratory 
repeatability and inter-laboratory reproducibility of the candidate test must be demonstrated, 
using calibrated sets of chemicals from a chemical bank and cells or tissues from a single 
source (Zurlo, 1998), together with the application of Good Laboratory Practice (GLP) 
(Cooper-Hannan, et al., 1999) and Good Cell Culture Practice (GCCP) (Coecke, et al., 2005; 
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Hartung, et al., 2002). The results must then be subjected to appropriate statistical analysis 
(Zurlo, 1998). A schematic representation of the ECVAM validation process is given in 
Figure 1.1, taken from Worth and Balls (2004). 
 
Figure 1.1. A schematic representation of the ECVAM validation process. 
 
 
After a formal validation has been completed, the next step is an independent evaluation of 
the goals, design, management, performance and outcome of the study, by one or more 
appropriate agencies, together with the publishing of a report in the peer-reviewed literature 
(Balls and Fentem, 1999; Goldberg and Locke, 2004).  
Efforts to define and coordinate the validation process have been made both in the United 
States and in Europe (Zurlo, 1998), and its scientific characteristics have been discussed on 
several occasions, being at the centre of some controversies as well (Balls, 1992; Flint, 1992; 
Green, 1992; Walum, 1992). However, today there is a wide literature on the principles of 
validation (Balls, et al., 1990a; Balls, et al., 1995; ICCVAM, 1997; OECD, 1996, 2005; 
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Walum, et al., 1994), even if the current reality recognizes that validation is only the first 
step. It can lead to scientific and industrial acceptance of the test and to the drafting of a 
proposed regulatory guideline, marking the beginning of the progression of the test towards 
regulatory acceptance and application (Balls and Fentem, 1999), but the path from validation 
to acceptance and implementation remains a long and arduous process (Goldberg, 2007). 
 
1.5.3. Regulatory acceptance 
A formal validation study is an important step on the way of regulatory application and 
acceptance of a new methodology (Balls and Fentem, 1999). The formal adoption of a 
validated test method by a regulatory agency/authority, which has to be considered also 
during the design and conduct of the validation study, is defined as "Regulatory Acceptance" 
of new or revised toxicological test methods, whose principles and criteria were developed 
simultaneously with validation criteria. These regulatory acceptance criteria (OECD, 2005) 
involve for example a transparent and independent peer review process of test method and 
validation study data; the fact that the test method should generate data useful for hazard/risk 
assessment purposes; that applicability and limitations of the test method should be clearly 
described; and also that the test method should be time and cost effective and likely to be 
used in a regulatory context. What it has to be considered, however, is that, in some cases, 
such as in the U.S., validation does not guarantee regulatory acceptance. Regulators do not 
necessarily require that agencies adopt formal validated alternatives; each agency can decide 
for itself whether a validated alternative test will be acceptable under its regulatory programs. 
Authorities simply need to be convinced that the proposed method performs to its intended 
use in measuring the endpoints in question for regulatory approval (Goldberg and Locke, 
2004; Wilcox and Goldberg, 2011). Anyway besides this, as it was concluded at a workshop 
held in Vouliagmeni, Greece, in 1990 "All conceivable and practicable steps should be taken 
to make the formal acceptance and incorporation on non-animal toxicity test procedures into 
regulatory practice as smooth and rapid a process as possible" (Balls and Fentem, 1999; 
Balls, et al., 1990b). 
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1.5.4. Validated and accepted alternative methods 
In Table 1.5 taken from AltTox.org (http://alttox.org/ttrc/validation-ra/validated-ra-
methods.html), a very useful website dedicated to advancing non-animal methods of toxicity 
testing, all the already validated and accepted alternative methods, updated at 27 September 
2011 are listed.  
Table 1.5. Validation and Regulatory Acceptance Status of Alternative Test Methods and 
Testing Strategies. 
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1.6. The legislative implementation of the 3RS 
principle 
As already discussed in Paragraph 1.3.2, the principles outlined by Russell and Burch (1959) 
received little attention until the animal welfare movement become a more important societal 
concern (Zurlo, 1998), and the Universal Declaration of the Rights of Animals (UNESCO, 
1978) was promulgated. Since then, active campaigns have been undertaken against 
manufacturers of cosmetics, household and personal care products and pharmaceuticals in 
attempts to stop animal testing, and significant pressure on government agencies took place to 
apply more stringent regulations on chemicals (Zurlo, 1998). As a consequence, several 
regulatory authorities have supported the principle of the 3Rs and several laws and directives 
regarding replacement, reduction, and refinement alternatives in scientific research 
throughout the world over the past decades. There are some primary events that had a 
profound impact on the research and development of alternative methods in toxicological 
testing, and are driving the need to examine the use of new and developing science in 
addition to traditional animal model approaches of safety testing worldwide. They are 
independent events, significantly different in their intended goals, that however have 
converged from vastly different directions and resulted in a common outcome: to drive the 
eventual replacement of animal testing (Wilcox and Goldberg, 2011). 
The first European Directives concerning safety in biotechnology experimentation date back 
to 1986 (Directive 86/609/EEC) (Council of the European Communities, 1986). Such 
Directive has several relevant aspects for the field of alternatives and, at least in theory, it 
represented a very strong driver for alternative methods. However, in practice there was very 
little enforcement of it, and that is why it was recently revised in 2010 (Directive 
2010/63/EU) (European Parliament, 2010), with the introduction of inspections and other 
reinforcements (Hartung, 2010, 2011). Regarding the aspects related to the field of 
alternatives, in these documents it is stated that: "An experiment shall not be performed if 
another scientifically satisfactory method of obtaining the result sought, not entailing the use 
of an animal, is reasonably and practicably available". The procedure which uses the 
minimum number of animals and which causes the least pain, suffering, distress or lasting 
harm must be chosen, and all experiments shall be carried out under general or local 
anaesthesia. Moreover, Article 23 of the 1986 Directive states: "The Commission and 
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Member States should encourage research into the development and validation of alternative 
techniques which could provide the same level of information as that obtained in experiments 
using animals but which involve fewer animals or which entail less painful procedures, and 
shall take such other steps as they consider appropriate to encourage research in this field." 
This article resulted to be very important, since it encouraged a substantial funding program 
for alternatives and their validation by the EU. More than € 250 million, indeed, was spent by 
the European Commission, and a similar amount was estimated to have been spent by the 
Member States (Devolder, et al., 2008; Hartung, 2010, 2011; Rusche, 2003). 
After that first Directive, the EU has shown a strong interest in animal well-being and has 
promulgated directives concerning animal protection in breeding (Directive 98/58/EC) 
(Council of the European Union, 1998), transport (Directive 95/29/EC) (Council of the 
European Union, 1995), slaughter (Directive 93/119/EC) (Council of the European 
Communities, 1993a), and the ill-treatment of animals as well (e.g. art. 727 of the Italian 
Penal Code). Also the Italian Legislative Decree 116/92 (Italy, 1992) can be added to these 
regulations, since it imposes some specific rules for the protection of animals used for 
experimental or other scientific purposes, and considers as an offence any experimentation on 
higher animals or any that affects their genetic identity, in particular if the experiment will 
inflict unnecessary pain and suffering (Passantino, et al., 2004). 
Of primary importance was also the adoption in 2003, by the EU institutions, of one of the 
most rigorous legislation enforcing the use of alternative methods, the 7th amendment 
(Directive 2003/15/EC) (European Parliament, 2003) of the 1976 European Cosmetics 
Directive (Directive 76/768/EEC) (Council of the European Communities, 1976; Hartung, 
2008a). It is stated in the 7th amendment: "Currently, only alternative methods which are 
scientifically validated by the ECVAM or the OECD and applicable to the whole chemical 
sector are systematically adopted at Community level. However, the safety of cosmetic 
products and their ingredients may be ensured through the use of alternative methods which 
are not necessarily applicable to all uses of chemical ingredients. Therefore, the use of such 
methods by the whole cosmetic industry should be promoted and their adoption at 
Community level ensured, when such methods offer an equivalent level of protection to 
consumers" (Hartung, 2011). Importantly, such Directive set out a timetabled schedule for 
banning animal testing for personal care products, permitting only the use of replacement 
alternatives. A complete ban on the use of animals for testing cosmetic products and their 
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ingredients on European territory, came into force on 11 March 2009. The marketing ban of 
products or cosmetic ingredients tested on animals became effective on the same date, except 
with regard to the tests involving repeated-dose toxicity, toxicokinetics and reproductive 
toxicity (the most complex endpoints) for which a deadline of ten years after entry into force 
of the Directive (11 March 2013) is foreseen. 
Similarly to the 7th amendment on cosmetics, also the Regulation (EC) No 1907/2006, better 
known as REACH Regulation (European Parliament, 2006, 2007) and adopted by the 
European Council and the European Parliament in December 2006, aims at avoiding animal 
testing and taking preference of alternative methods to animal testing as far as possible 
(Lilienblum, et al., 2008). This regulation is the first one in Europe to combine the issue of 
the 3Rs (therefore the need for the replacement, reduction, and refinement of animal 
experiments) with the need to implement the knowledge about the hazard of chemicals and 
the willing to harmonize the testing requirements for existing chemicals for which there is a 
lack of safety data and new ones (Zuang and Hartung, 2005). Because of its primary 
importance in the treated issue, REACH Regulation will be discussed in more details in 
Chapter 2. 
 
1.7. Numbers of animals used 
As a result of all the above mentioned laws and regulations, the development of test methods 
for characterizing human exposure to chemicals of toxicological concern have proceeded 
rapidly and will continue to do so in the foreseeable future (Wilcox and Goldberg, 2011). 
However, despite all the steps made in the field of in vitro models aiming at the reduction of 
the total number of animals used for experimental and other scientific purposes, that number 
is still quite high. Indeed, as reported in the 6th Commission Report on the Statistics on the 
number of animals used for experimental and other scientific purposes, that includes data 
from all the 27 Member States of the EU, in 2008 it was just above twelve million (European 
Commission, 2010a). 
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Mammals are often used as experimental species and, as also stated in the Report, rodents 
and rabbits represented more than 80% of the total number used in Europe. Among them, 
mice are by far the most commonly used species, accounting for 59% of the total use, 
followed by rats with 18%. Cold-blooded animals represent instead almost 10% of the total, 
and are considered as the second most used group, while the third largest one was represented 
by birds (a little over 6% of the total) (cf. Figure 1.2).  
 
Figure 1.2. Percentages of animals used by classes in the Member States. 
 
 
 
Among the total number of animal used for experimental purposes in many different areas, 
toxicological and other safety evaluations for different products and environmental tests 
represented around the 8,7% of the total, i.e. more than one million of animals (cf. Figure 
1.3).  
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Figure 1.3. Purposes of experiments. 
 
 
 
 
Of this total, animals used for toxicological or other safety evaluations of products or devices 
for human and veterinary use represented the largest number (almost 51%). The percentage 
of animals used for toxicological evaluation additives in food for human consumption, 
cosmetics and household products, is very small (1,18%) when compared to the other product 
groups, thanks to new regulations, while in the case of evaluation of industrial and 
agricultural products, the numbers are respectively represented by 7,1% and 7,9% of the 
number of animal used for that purpose. There are then other toxicological and safety 
evaluations that represent more than 21% (cf. Figure 1.4).  
 
 
 
59 
 
Figure 1.4. Number of animals used in toxicological and other safety evaluation. 
 
 
 
There is a clear decrease in the number of animals used for toxicological tests for products 
intended for industry, for agriculture and for potential contaminants of the environment, in 
comparison to the data submitted in the previous statistical report (European Commission, 
2007a). There is also a significant decrease, represented by a 65% drop, in the number of 
animals used for testing of products for cosmetics and toiletries, that should be seen in light 
of the legal requirement to phase out animal testing for cosmetics in Europe. 
The development of alternative methods is thus of high priority in order to reduce the number 
of animals that are nowadays considered to be necessary for safety evaluation of human 
health and environment (Rogiers, 2005). 
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Chapter 2  
REACH, a new chemicals policy for the 
EU 
“REACH is all about protecting human health and the environment The challenge 
is to have scientifically sound information on the potential hazards of substances 
whilst at the same time minimising unnecessary animal testing. One of the 
fundamental aims of REACH is to promote alternative methods for assessing 
hazards of substances and to see animal testing as a last resort. All parties involved 
should take this very seriously.” 
- Geert Dancet, Executive Director of ECHA - 
 
 
2.1. Introduction 
REACH is a new European Community Regulation on chemicals and their safe use 
(Regulation (EC) No 1907/2006) (European Parliament, 2006, 2007), which concerns the 
Registration, Evaluation, Authorisation and Restriction of CHemicals (from what derived the 
acronym REACH), and replaces different European Directives and Regulations on chemicals 
(more than 40 existing pieces of legislation) with a single system, in order to optimize and 
improve the former legislative framework of the European Union (EU).  
A large number of substances, indeed, have been manufactured and placed on the market in 
Europe for many years along the course of history, sometimes in very high amounts, but there 
was insufficient information about most of chemicals and the hazards that they pose to human 
health and the environment (Danish Board of Technology, 1996). With regard to these 
chemicals, an important distinction between "existing" and "new" chemicals, based on the 
cut-off date of 1981, was introduced with the Regulation (EEC) 793/93 of 23 March 1993 on 
the evaluation and control of the risks of existing substances (Council of the European 
Communities, 1993b). All the chemicals listed in the European Inventory of Existing 
Commercial Chemical Substances (EINECS) (created by the European Community 
Commission Decision 81/437/EEC and including more than 100.000 chemicals) 
(Commission of the European Communities, 1981) and reported to be on the European 
market between 1 January 1971 and 18 September 1981 were called "existing"; on the 
contrary, all those chemicals introduced after 1981 and listed in the European List of Notified 
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Chemical Substances (ELINCS) (Sauer, 2004) were defined as "new" chemicals. The 
problem was that, while all of these "new" substances, before being placed in the market, had 
to be tested quite rigorously, the "existing" ones, which represented 99% of the market, were 
not subject to such requirements. Therefore, it is clear how it was relatively costly to 
introduce a new substance on the market, and this of course represented a brake to the 
expansion and innovation of EU chemicals industry, because the research of new compounds 
was discouraged, in favour of the development and use of existing substances (European 
Commission, 2006). At the same time, because there was a general lack of knowledge on 
properties and uses of "existing" substances, the process of identification and risk assessment 
was slow and resource-intensive, thus not allowing the system to work efficiently and 
effectively. Moreover, also the introduction of risk management measures was delayed, 
leaving EU industries of chemicals behind their U.S. and Japanese counterparts. As a 
consequence, there was an obvious need to fill these information gaps to ensure that industry 
was able to assess hazards and risks of the substances, and to identify and implement the risk 
management measures to protect both humans and the environment (Commission of the 
European Communities, 1998; Sauer, 2004). Because of this awareness, a period of intense 
negotiations, discussions and highly controversial debate started, leading to the amendment 
of the new law in 2006, which has been considered for its importance, an historical date 
(Fuchs, 2009). 
REACH Regulation, which officially came into force the 1st June 2007 (ECHA, 2007), 
replaced old legislations, encouraging innovation of safer substances and establishing a 
system for assessing both existing and new chemicals. Specifically, it has several aims, but 
the most important ones, concerning this thesis work, are to improve the protection of human 
health and the environment from the risk of hazardous chemicals, and to promote alternative 
methods for the assessment of hazards of such substances (a list of all the Regulation recitals 
and articles on this matter is provided in Appendix 1). Other aims of primary importance are 
maintaining and enhancing the competitiveness of the EU chemicals industry, which is a key 
sector for the economy of the whole EU, as well as promoting its integration with 
international efforts, ensuring the free circulation of substances on the internal EU market by 
increasing transparency, and preventing its fragmentation. Moreover, the Regulation aims to 
the progressive substitution of the most dangerous chemicals when suitable alternatives have 
been identified.  
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In order to do that, REACH Regulation places greater responsibility on industry to manage 
the risks posed by chemicals to the health and the environment, and to provide appropriate 
safety information on the substances to their users prior to production and marketing, while 
the role of authorities should be to ensure that industries meet their obligations and take 
actions on substances of very high concern or where there is a need for community action. On 
the contrary, the previous legislation required public authorities to identify and address 
possible safety issues for the chemicals on the market, and what was required was a 
comprehensive risk assessment, rather than a more specific one. This shift of responsibility 
towards producers and importers is a crucial element of REACH, and sometimes defined as a 
"self-responsibility approach" (Fuchs, 2009; Führ and Bizer, 2007). Moreover, another 
important point is that all manufacturers, importers and also for the first time downstream 
users of chemicals are required to collect information on the properties of their chemical 
substances and identify and manage the risks, facilitating their safe handling.  
For these purposes, REACH required also the set-up of the European Chemicals Agency 
(ECHA), based in Helsinki, Finland, which started operations on 1 June 2008 and acts 
autonomously as the central point in the REACH system, coordinating and implementing role 
in the overall process. The Agency run the databases necessary to make the system operative, 
coordinates the evaluation of suspicious chemicals and it is also building up a public database 
where consumers and professionals can find hazard information. The Agency will therefore 
manage the technical, scientific and administrative aspects of the REACH system at a 
Community level, aiming to ensure that the legislation can be properly implemented and has 
credibility with all stakeholders. 
 
2.2. Scope: REACH and chemicals  
REACH Regulation is very wide in its scope, indeed it covers all substances (both new and 
existing ones) whether manufactured, imported, used as intermediates or placed on the 
market in the EU, either on their own, in preparations or in articles, unless they are 
radioactive, subject to customs supervision, or are non-isolated intermediates. These 
substances are excluded from the REACH Regulation because of some articles (Article 2, 56 
and 67) and some of these exemptions are made on the basis of other equivalent legislation 
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(e.g. the Council Directive 96/29/Euratom on protection of health against the dangers arising 
from ionising radiation (Council of the European Union, 1996), the Regulation (EC) No 
726/2004 on medicinal products (European Parliament, 2004), or the Council Directive 
89/107/EEC on food additives in foodstuffs) (Council of the European Communities, 1988).  
A review of the scope of the Regulation has been foreseen by the Commission five years after 
entry into force, as stated in Article 138(6) of REACH: "By 1 June 2012 the Commission 
shall carry out a review to assess whether or not to amend the scope of this Regulation to 
avoid overlaps with other relevant Community provisions. On the basis of that review, the 
Commission may, if appropriate, present a legislative proposal."  
 
2.3. How does reach work: REACH processes 
REACH, as already said, stands for Registration, Evaluation, Authorisation and Restriction of 
Chemicals, and its entire process is organized in different phases and deadlines. 
 
2.3.1. Pre-Registration  
The process began with a mandatory pre-registration deadline of December 2008. 
Manufacturers and importers of chemicals had to pre-register substances already present on 
the EU market (the so-called phase-in substances), in order to benefit from transitional 
arrangements, and also to share data with other registrants, avoiding therefore carrying out 
redundant tests. The pre-registration period was limited from 1 June 2008 to 1 December 
2008, and a total of 180,000 pre-registrations were expected by about 27,000 companies for 
30,000 substances. ECHA, however, received more than 2.7 million pre-registrations from 
about 65,000 companies for 144,000 substances (Hartung, 2011). 
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2.3.2. Registration  
The 2nd scheduled phase was Registration, that first applied from 1 June 2008. REACH 
requires manufacturers and importers to obtain information on the physicochemical, health 
and environmental properties of their substances, to use them to determine how these 
substances can be used safely, and then to submit a registration dossier documenting data and 
assessments to the ECHA Agency. These requirements are used for substances produced or 
imported in quantities of 1 tonne or more per year per company (threshold much higher than 
the previous one of 10 kg for new substances). Quantities above 10 tonnes per year, instead, 
additionally require the submission of a Chemical Safety Report (CSR) in order to document 
the safety assessment of the substance (European Commission, 2006). Test requirements 
progressively increase with the volume of the specific chemical substance. For instance acute 
toxicity tests are required for substances produced or imported between 10 and 100 tonnes 
per year, subchronic toxicity tests for substances between 100 and 1000 tonnes per year and 
chronic toxicity/carcinogenicity studies for substances >1000 tonnes per year. Table 2.1, 
taken from Hengstler et al. (2006), shows all the required tests for the different categories. 
From a practical point of view, the detailed compilation of the required tests is one of the 
most important parts of the REACH proposal. 
 
2.3.3. Evaluation  
Once the registration dossier has been received, the Agency has then to perform two types of 
evaluation with different aims. Firstly, it has to perform a dossier evaluation, to check if 
information provided by industries is compliant with the requirements, and to assess the 
testing proposals made by the registrant, in order to ensure that the assessment of the 
chemical substances will not result in unnecessary testing, especially on animals. The Agency 
will also coordinate substance evaluation, which has to be conducted by the Member States to 
investigate chemicals of concern, in order to clarify suspicions of risks to human health or the 
environment by requesting further information from industry. This assessment will start in 
2012 and it may lead authorities to the conclusion that action needs to be taken under the 
restrictions or authorisation procedures in REACH, or that information needs to be passed on 
to other authorities responsible for relevant legislation.  
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Table 2.1. Tests required by the REACH concept. 
 
 
2.3.4. Authorisation  
REACH also provides for an authorisation system for the use of substances of very high 
concern (i.e. carcinogens, mutagens, toxic to the reproductive system, bio-accumulative and 
so on), because of their very serious and normally irreversible effects on humans and the 
environment. It is therefore essential to regulate them centrally, through a mechanism that 
ensures that the risks related to their actual uses are assessed, considered and then decided 
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upon by the Community. Therefore, the aim of the authorisation system is to ensure that risks 
associated with these substances are adequately controlled, and that they will be 
progressively substituted by safer substances or technologies, when technically and 
economically feasible, or only used where there is an overall benefit (i.e. socio-economic 
benefits) for the society that outweigh the risks.  
 
2.3.5. Restriction  
In addition, EU authorities may impose restrictions and prohibit or set conditions for the 
manufacture, placing on the market or use of certain dangerous substances or group of 
substances when unacceptable risks to humans or the environment have been identified. The 
use of certain dangerous chemicals is acceptable as long as appropriate risk management 
measures are implemented, such as the use of good ventilation or protective clothing. If 
measures at company level are not sufficient to keep the risks acceptable, restrictions and  
limitations can be imposed for substances in certain circumstances and for certain uses (for 
instance by consumers), or even complete bans on all uses (European Commission, 2006, 
2007b). Thus, the aim of restrictions is to act as a safety net in order to manage risks that are 
otherwise not adequately controlled.  
Restriction provisions of REACH (included in Annex XVII of the Regulation) came into 
force from 1 June 2009 and were updated through several amendments in 2009 (Commission 
Regulation (EC) No 552/2009) (Commission of the European Communities, 2009), 2010 
(Commission Regulation (EC) No 276/2010) (European Commission, 2010b) and 2011 
(Commission Regulation (EC) No 207/2011; Commission Regulation (EC) No 366/2011; 
Commission Regulation (EC) No 494/2011) (European Commission, 2011a, 2011b, 2011c). 
 
2.3.6. Classification and labelling inventory  
Another important point for chemicals legislation in Europe has always been the requirement 
for industry to classify and label dangerous substances and preparations according to standard 
criteria. The aim of this requirement is ensuring that hazard classifications and consequent 
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labelling of all dangerous substances manufactured in or imported into the EU are available 
to all, in order to promote agreement on the classifications. Indeed, most divergences between 
classifications of the same substance should be removed over time, either through co-
operation between notifiers and registrants, or by EU harmonised classifications for 
substances.  
Regarding this matter, REACH builds on existing legislation, and the European Commission 
adopted on 27 June 2007 a new proposal for a Regulation on classification, labelling and 
packaging of substances and mixtures (Commission of the European Communities, 2007), 
that incorporates the classification criteria and labelling rules agreed at United Nations level, 
the so-called Globally Harmonised System of classification and labelling of chemicals (GHS) 
(ONU, 2009).  
 
2.3.7. Communication in the supply chain 
Communication in the supply chain is another important requirement of REACH. The aim is 
to ensure that not only manufacturers and importers, but also their customers (i.e. 
downstream users and distributors), have the information they need in order to use chemicals 
safely, and therefore information relating to health, safety and environmental properties, risks 
and risk management measures are required to be passed both down and up the supply chain. 
This will be done via the well-established and familiar Material Safety Data Sheet (MSDS) 
for all dangerous substances. Indeed, the provisions of the current Safety Data Sheets 
Directive (Directive 91/155/EEC) (Commission of the European Communities, 1991a) were 
carried over into the REACH. As more information on hazardous properties and information 
that challenges the quality of risk management measures will be available as a result of 
registrations, the quality of MSDSs will be improved, and also relevant exposure scenarios 
need to be annexed to them and have thus to be passed down the supply chain.  
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2.4. Timeline for REACH implementation  
REACH aimed to ensure a smooth transition from the previous legislation, and therefore will 
be implemented gradually until May 2018. Appropriate deadlines for the repeal of various 
aspects of the previous legislation and for the phasing in of various provisions of REACH, 
indeed, has been set, with the aim of not wasting the work undertaken under the previous 
legislation.  
The scheduled deadlines are listed in what follows: 
1 June 2007: Entry into force of REACH. 
1 June 2008: European Chemicals Agency became operational. 
1 June 2008 to 1 December 2008: Pre-registration of so-called "phase-in substances".  
30 November 2010: Registration deadline for substances produced or imported in quantities 
of 1000 tonnes and above, as well as carcinogens, mutagens and substances toxic to 
reproduction (CMR category 1 and 2) equal to or greater than 1 tonne/year, and substances 
classified as very toxic to aquatic organisms (R50/53) at and above 100 tonnes/year.  
31 May 2013: Registration deadline for substances produced or imported in quantities equal 
to or greater than 100 tonnes/year. 
31 May 2018: Registration deadline for substances produced or imported in quantities equal 
to or greater than 1 tonne/year (European Commission, 2006, 2007b). 
The yearly tonnage refers to metric tons per manufacturer or importer, not to the total volume 
manufactured or imported (Rudén and Hansson, 2010). 
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2.5. Impact assessment 
At the time when the REACH Regulation was negotiated and adopted (2003-2006), the 
European Commission conducted various studies to assess its possible impact. Before 
adopting its proposal on REACH in October 2003, the Commission published an Extended 
Impact Assessment (Commission of the European Communities, 2003), which assessed the 
benefits for health and the environment, as well as the costs for industry and the Agency.  
 
2.5.1. Benefits 
The most important benefits expected from REACH will be benefits to health and the 
environment, mainly due to the expected improvement of the risk management. A 
comprehensive quantitative assessment of the wide range of environmental and health 
impacts, however, is not possible, due to a lack of data. 
An important benefit of REACH is that the hazards and risks of chemicals are more 
systematically identified. This allows for more effective risk management measures by 
industries and enterprise producing, handling and using these substances, and for end-users 
exposed to these substances, providing at the same time also a benefit for consumers, who 
will have access to more information on the potential hazards and risks of chemicals 
(European Commission, 2006, 2008). Authorities as well will benefit from the information 
gathered, as it should eventually lead to a better management of the risks associated with 
individual substances and uses, potentially yielding added benefits for the workforce exposed 
to these chemicals and for society at large, including an improved status of the environment. 
It will be possible indeed to ensure more effective implementation of the precautionary 
principle, being alerted at an earlier stage to potential risks and acting more rapidly to address 
the problem. 
REACH will contribute also to a positive occupational impact (resulting in health benefits for 
workers, both in chemicals and downstream sectors) and public health impact, because it is 
well known that the exposure to chemicals is linked with a considerable number of diseases, 
including respiratory and bladder cancers, mesothelioma, skin disorders, respiratory diseases, 
eye disorders, asthma and others, even if most harmful effects are the result of many causes 
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acting together, such as genetics, lifestyle, radiation, diet, pharmaceuticals, chemicals 
(manufactured and natural), smoking and air pollution, including indoor and outdoor 
exposures. Moreover, sensitive groups, such as the elderly, children, the embryo, the sick, 
and pregnant women, may be affected at much lower doses than others. However, it is 
frequently very difficult to link diseases to particular chemicals and estimate the aggregate 
health impacts, but despite of this, the anticipated benefits are generally expected to be 
significant. In the Extended Impact Assessment of the Commission proposal (Commission of 
the European Communities, 2003), diseases caused by chemicals were assumed to account 
for some 1% of all types of disease in the EU. Assuming a 10% reduction in these diseases as 
a result of REACH (implying that 90% of the health impacts associated with chemicals are 
either related to historical exposures, will not be identified by REACH or cannot be tackled), 
a 0.1% overall reduction would result in the EU. This would be equivalent to around 4,500 
deaths due to cancer being avoided every year. On the basis of a € 1 million value of life, the 
potential health benefits of REACH were then estimated approximately € 50 billion over a 30 
year period. This figure was based on an illustrative scenario developed with the support of 
recognised international organizations, such as the World Bank and World Health 
Organisation, and it is not an estimate of the benefits of REACH, but rather an illustration of 
their potential scale.  
It is clear that exposure to hazardous chemicals also damages the environment. However, due 
to lack of data, also in this case it is not possible to provide, as already mentioned, a 
comprehensive quantitative assessment of the impacts on the environment. Much of the 
information needed will only be available after the chemicals on the market today have been 
tested and registered in line with the requirements of REACH (Commission of the European 
Communities, 2003; European Commission, 2003). Anyway, it is possible to say that 
REACH will contribute to reduced pollution of air, water and soil, as well as to reduced 
pressure on biodiversity, even if on a long-term period, since chemicals get into the 
environment in a number of different ways. Improved control of persistent bio-accumulative 
and toxic substances is needed to ensure that these substances are prevented from polluting 
the environment, as once there they are very difficult to remove. 
The proposal includes also a series of measures and requirements that will influence the 
direction of industrial innovation, both at product and process development level, as well as 
at organisational level. The modifications made to the chemical Research and Development 
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(R&D) regime by the introduction of the REACH system give more flexibility and they will 
facilitate R&D, especially in the longer-term, while in the short-term much will depend on 
the resource available. The new system may also lead to induced innovation in the chemicals 
industry towards the development of new and safer products and processes, and it may also 
create an incentive for the use and development of such new and safer substances, therefore 
encouraging innovation. 
In summary, the data available indicate that there are significant health and environmental 
impacts associated with certain chemicals. A better knowledge of the properties of chemicals, 
acquired through REACH, can be expected to result in better safety and control measures, 
reducing exposure and hence, the impacts on human health and the environment, besides 
helping a better implementation of existing legislation. 
 
2.5.2. Costs 
With regards to costs, and considering a combination of the estimates of direct and indirect 
costs, the Extended Impact Assessment of the Commission’s proposal of October 2003 
(Commission of the European Communities, 2003) has estimated the overall costs for 
chemical industry and its downstream users to fall in the range of € 2.8 - 5.2 billion. These 
costs will be incurred over a period of 11 (the time to register all substances currently on the 
EU market) to 15 years (to allow for a longer adjustment period).  
Specifically, the expected direct costs to the chemicals sector, which include testing and 
registration costs, together with Agency fees (paid by industry as contribution to the running 
of it) as well, were estimated to be approximately € 2.3 billion over the 11 years soon after 
the entry into force of the Regulation. The estimate assumed a high level of sharing 
information and cooperative actions between stakeholders, and it was based on the assumed 
availability of validated computer-based methods (Quantitative Structure-Activity 
Relationships or QSARs), that should allow for a significant reduction in testing costs to the 
chemicals sector. These methods permit the prediction of physiochemical, environmental, or 
health effects based upon the molecular structure of a chemical, without the need for costly 
animal testing. However, the reduction in testing costs arising from the availability and use of 
QSARs is conditional on the validation, acceptance and use of such techniques on a large 
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scale and their practical application for regulatory purposes (Commission of the European 
Communities, 2003; European Commission, 2003). Since such estimations have been made, 
administrative costs for companies have been further decreased, due to changes such as 
reduced testing and reporting requirements and simplified registration procedures for low 
volume chemicals, exclusion of polymers from registration, and a major reduction in 
downstream user requirements. However, the general estimates remains the same because, at 
the same time, the costs of the Agency increased significantly, due to the fact that the Council 
and Parliament have added substantial new responsibilities, in particular for ensuring a 
harmonized approach to the evaluation of registration dossiers (European Commission, 
2006). 
Considerable attention has been focused also on the implications of the REACH system for 
downstream users of chemicals and the costs estimated for them. Predictions of costs were 
made on the basis of normal business behavior in response to changes in the market and the 
expert knowledge of the competitive situation of all the sectors and subsectors involved 
(Commission of the European Communities, 2003). The impact on downstream users results 
mainly from higher prices of chemicals, due to testing and registration costs, and from the 
costs related to the need to find substitutes for withdrawn chemical substances and 
preparations (European Commission, 2003). 
As reported in the Extended Impact Assessment of 2003 (Commission of the European 
Communities, 2003), two scenarios for the costs of REACH to downstream users have been 
investigated: a "normal expectations" scenario, which is what under normal circumstances the 
Commission expects should happen and a "higher substitution costs" scenario, which cannot 
be excluded. Both scenarios are based upon estimated testing and registration costs of € 2.3 
billion, i.e. including both testing and registration costs and Agency fees. In each case, a 
lower and upper estimate of the costs is derived for two time periods: 11 and 15 years.  
The "normal expectation" case examines the impact of the introduction of REACH, where the 
implications for downstream users come only from the pass-through of testing and 
registration costs and the effects of the withdrawal of chemical substances on individual 
downstream users.  
A "higher substitution costs" scenario illustrates the effects where the withdrawal of 
substances further increases the costs of substitution, through the cumulative effects of the 
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withdrawal of substances in terms of adaptation to the whole of the chemicals supply chain. 
In this case, it has been assumed that the efficiency of the chemicals industry is reduced 
marginally in proportion with the withdrawal of chemical substances. It also results in some 
increase in the market power of the suppliers of substitution substances. In this case, higher 
downstream user costs would be expected.  
In the "normal expectation" case, the costs to downstream users of the introduction of 
REACH is assessed to be in the range € 2.8 - 3.6 billion. These costs will occur in the form of 
higher chemical prices resulting from the passing through of testing and registration costs and 
as a result of the additional substitution costs for downstream users of chemicals in finding 
potentially higher cost or less-effective replacements for those substances removed from the 
market. In the "higher substitution cost" scenario, the costs to downstream users of the 
introduction of REACH is assessed to be in the range € 4.0 - 5.2 billion.  
In summary, costs to downstream users were estimated in the Commission’s Impact 
Assessment of 2003 at € 0.5 to 1.3 billion, under the assumption that 1 to 2 % of the 
substances would be withdrawn because continued production would no longer be profitable. 
Costs could rise to € 1.7 - 2.9 billion when industry would face higher substitution costs in 
the downstream supply chains (European Commission, 2006). 
Table 2.2 and 2.3 from the Extended Impact Assessment (Commission of the European 
Communities, 2003) show testing and registration costs of REACH and estimated cost to 
industry and downstream users, respectively. 
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Table 2.2. Testing and registration costs of REACH. 
 
 
Table 2.3. Summary of estimated costs to chemical industry and downstream users (these 
estimates include costs passed on from the chemicals sector to downstream users). 
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2.6. REACH and animal testing. 
Protecting the health and the environment from adverse effects due to dangerous chemical 
substances clearly includes also animals. The REACH Regulation indeed, as already said, has 
been designed also to reduce animal testing to the absolute minimum and, in line with the 
3Rs principle (Russel and Burch, 1953), it requires to cause the minimum of distress and 
suffering to the animals when experiments are essential. It is clear how acquiring the 
necessary knowledge on the properties of substances necessarily requires some animal testing 
(European Commission, 2006). However, in order to minimise the number of animal tests, 
and therefore lessen its impact on animal use, the REACH Regulation provides a number of 
possibilities to adapt the testing requirements, using existing data and alternative assessment 
approaches (ECHA, 2009). 
Unnecessary tests can be avoided mainly due to the obligation, for companies that are testing 
the same chemicals, to share their data, in order to ensure no duplication of animal testing. 
Available studies (such as studies from other countries, previous animal testing, available in 
vitro data, epidemiological studies, etc.) have to be shared and safety testing have to be 
carried out only when no data are available. An important point, in this regard, is that 
companies will face penalties if they don’t comply (Commission of the European 
Communities, 2003). 
Furthermore, in order to decrease the duplication of animal testing, before performing new 
test on animals for testing high volume chemicals, the testing proposals must be approved by 
the Agency, and it would happen only if existing information and validated alternative 
methods are not sufficient. To further improved the situation, a public consultation period of 
45 days before carrying out certain tests was also introduced, with the aim to verify whether 
the data is already available and consequently if the tests are necessary or not. On the 
contrary, for low volume chemicals, as far as possible, no animal testing will be required at 
all. In particular, REACH promotes the use of QSARs as a cheap alternative that does not 
involve animal testing. All these factors aim to ensure that the endpoints studied are relevant, 
that the scientific validity of the research is sufficiently high, and that the testing programme 
does not duplicate other studies (Commission of the European Communities, 2003; European 
Commission, 2006). 
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However, new tests must be optimized, standardized and validated before they can be 
accepted by regulatory authorities for replacing conventional animal studies, and these 
procedures normally take several years (Hartung, et al., 2003, 2004; Zuang and Hartung, 
2005). Although several promising innovative techniques are available today, they have not 
yet been sufficiently validated with regard to their use in safety assessment, and a premature 
replacement of animal studies would impair the benefits of REACH, and would be 
counterproductive for the consumers’ health and block further progress in development of 
toxicological testing strategies (Hengstler, et al., 2006). Therefore, it is clear how the 
REACH concept will cause a transient increase in animal experiments in the years following 
its introduction, since many substances will have to be tested in conventional animal 
experiments.  
When REACH was negotiated, between 2001 and 2005, several attempts were made to 
estimate the costs of the regulation, both financially and in terms of the number of animals 
used (Hartung and Rovida, 2009). Various estimates of the number of tests and consequently 
the number of laboratory animals required by REACH regulation were made to better address 
the problem. In general, it has been estimated an increase of 3% of animal testing (especially 
on rats and mice) in the EU for the first eleven years after the adoption of REACH. The 
Commission initially estimated the number of laboratory animals required to 2.6 million 
(range of estimate 2.1-3.9 million) (Van der Jagt et al., 2004), but this number was actually 
wrong, not taking into consideration the number of offspring produced during reproductive 
toxicity testing. Subsequent estimates, that include the offspring produced during testing, 
were obviously higher, reaching approximately 9 million laboratory animals (with a financial 
cost of approximately € 1.6 billion) (Höfer et al., 2004).  
The scenario was obviously not bright. Moreover, two important publications of 2009 
(Hartung and Rovida, 2009; Rovida and Hartung, 2009) questioned these estimates, 
suggesting even much higher numbers, mainly due to changes to the final legislation, such as 
the inclusion of reaction intermediates, and changes to the guidance for industry on how to 
test, together with an increased number of EU members. The study published by Rovida and 
Hartung (2009) suggested, indeed, that the testing required would involve 54 million 
vertebrate animals and that the costs would amount to € 9.5 billion. However, this study has 
been reviewed by the ECHA, who luckily concluded that the real figures are more likely to 
be the ones as originally provided in the Commission impact assessments (Commission of the 
77 
 
European Communities, 2003), and that the study overestimated the impact of the legislation 
by six times, because overestimating the subsequent factors:  
1. The probable number of substances that will be registered under REACH and require 
a full data set, which has been overestimated in the paper by almost two fold, mainly because 
the assumptions are not justified and seem to be incorrect.  
2. The probable number of tests and laboratory animals required, which has been 
overestimated approximately by six times, mainly because the availability of existing 
information and the possibilities for adapting the information requirements are not taken into 
account, and also because the rules for requesting testing in a second species are not 
interpreted correctly;  
3. The probable costs for conducting the tests, which have been overestimated by 
approximately the same factor (ECHA, 2009). 
For all these reasons, the REACH concept has been discussed controversially between 
different animal welfare groups, that press so that animal experiments could be replaced by in 
vitro techniques on a much larger scale. For instance Greenpeace principally appreciates the 
REACH concept, but demands an acceleration of the introduction of non-animal alternatives 
(http://www.greenpeace.org/eu-unit/en/). It is clear how, after the initial period when an 
increased number of animals foreseen, such number would strongly decrease. It is supposed, 
indeed, that the lack of knowledge about a wide range of substances in use today should be 
adequately addressed and therefore, only a few new substances per year will have to be 
tested, leading to a decrease of the animals required (Hengstler et al., 2006). The primary 
importance of the REACH Regulation in the field of animal testing is therefore evident, even 
if clearly the benefits will occur over a longer time frame. 
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Chapter 3  
Evaluation of the use of human 
Mesenchymal Stem Cells for acute 
toxicity tests 
 
3.1. Introduction  
Poisoning is generally recognized as a severe health problem. The Institute of Medicine 
(IOM) estimates that more than four million poisoning episodes occur annually in the United 
States (ICCVAM, 2006a; IOM, 2004). For this reason, in vivo toxicological testing designed 
to assess the acute oral toxicity of chemicals is required by regulatory authorities all around 
the world to provide classification and labelling warning of the possible consequences of oral 
exposure to a chemical. However, the utility of the data obtained in these in vivo tests for the 
purpose of predicting the effects occurring in humans has been often questioned (Balls, 1991; 
Basketter et al., 1997; Langley et al., 2005; York et al., 1996; York and Steiling, 1998). 
Thus, the replacement of in vivo tests with in vitro alternatives has reached a high priority 
level. Recently, many in vitro methods for toxicity testing have been developed as 
alternatives to whole animal tests according to the 3Rs approach – Reduction, Replacement 
and Refinement – started in 1959 by Russell and Burch (1959). Clearly, the replacement 
and/or reduction of unnecessary in vivo tests would have significant animal welfare benefits 
and would also result in lower testing costs and time (Ukelis et al., 2008). To this aim, 
several cell lines have been used for in vitro toxicity tests (Ekwall, 1983; Evans et al., 2001; 
Gennari et al., 2004), that are typically carried out with immortalized cell lines or primary 
cells, which are directly isolated from animal tissues. Immortalized cells are readily available 
and easily maintained, although they usually show anomalous behavior and phenotypes, 
which do not reflect the mechanism observed in their normal homologous cells. In particular, 
primary cells are considered a better option as model systems for predicting toxicological 
behavior, although they are limited in quantity and suffer from batch to batch variation. Two 
different cell lines, mouse fibroblast (BALB/c) 3T3 cells and Normal Human Keratinocytes 
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(NHK), have already been validated by ICCVAM for predicting cytotoxicity in vitro 
(ICCVAM, 2006a, 2006b). Both these validated methods not only take advantage of the 
Neutral Red Uptake (NRU) assay for determining the in vitro cytotoxicity of test substances, 
but also exploit the in vitro generated data for determining starting doses for in vivo acute oral 
systemic toxicity tests using the linear relationship between IC50 values (50% Inhibitory 
Concentration) obtained from NRU assay and rodent oral LD50 values (50% Lethal Dose) 
established by the Registry of Cytotoxicity (RC). The original linear regression formula, i.e. 
the so called RC millimole regression, was proposed by ZEBET, the German National Centre 
for the Documentation and Evaluation of Alternative Methods to Animal Experiments, as a 
method to reduce animal use by identifying the most appropriate starting doses for acute oral 
toxicity tests (Halle, 1998, 2003; Spielmann et al., 1999). Subsequently, in the framework of 
the ICCVAM Validation Study, two new regressions were developed in order to improve not 
only the RC millimole regression, but also its ability to accurately predict LD50 values from 
IC50 ones, and finally to make this approach relevant to test mixtures and substances whose 
molecular weight is unknown. 
The 3T3 and NHK NRU test methods are today the in vitro basal cytotoxicity assays 
recommended for determining starting doses for acute oral toxicity tests using rats, although 
both these methods are not sufficiently accurate as stand-alone ones to correctly predict acute 
oral toxicity for the regulatory hazard classification purpose (ICCVAM, 2006b). The 
ICCVAM Test Methods Evaluation Report recommends that, for a new candidate in vitro 
basal cytotoxicity test, the correlation between in vitro and in vivo test methods must be 
quantitatively established by using at least twelve substances that cover all six hazard 
classification categories. In addition, the performance of the test method should be 
comparable to or better than the accuracy and reliability of the 3T3 and NHK NRU methods. 
In this study we use, for the first time to our best knowledge, human Mesenchymal Stem 
Cells (hMSCs) as cell line in order to develop a novel in vitro model system for acute toxicity 
test of chemicals. The unique properties of hMSCs, such as unlimited proliferation ability, 
plasticity to generate other cell types and more readily available sources of human cells, 
clearly identify their potential benefits in toxicology (Davila et al., 2004). Specifically, the 
aim of this study was to evaluate the applicability of hMSCs as cell line for in vitro 
cytotoxicity tests to correctly predict LD50 and the hazard category according to the Globally 
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Harmonized System of Classification – GHS (ONU, 2009), and finally to compare their 
behavior with the validated 3T3 and NHK NRU test methods. 
 
3.2 Material and methods  
3.2.1. Isolation of Mesenchymal Stem Cells  
After obtaining informed consent, fifteen milliliters of bone marrow aspirate, taken from the 
iliac crest of two human donors, were diluted with equal volume of phosphate-buffered saline 
(PBS, Sigma, St. Louis, MO, USA). Mononuclear cells were isolated by a Ficoll-Paque 
density gradient centrifugation (Hystopaque 1077, Sigma, 30 min, 800 x g), and subsequently 
washed in PBS (10 min, 400 x g). Possible residual red blood cells were lysed using a 
commercial lysing solution (BD Pharm lyse, Milano, Italy). After centrifugation (5 min, 300 
x g), the pellet was resuspended in complete culture medium constituted by αMEM (Sigma), 
20% fetal bovine serum (FBS, Sigma), 1% penicillin/streptomycin solution (Sigma), and 2 
mM L-glutamine (Sigma). Nucleate cells were counted by haemocytometer and plated at a 
density of 0.6-1 x 106 cells/cm2 in uncoated Petri dishes. After overnight incubation at 37 °C 
under a humidified atmosphere containing 5% CO2, non-adherent cells were removed and 
fresh medium was added. By eliminating the remaining non-adherent cells through complete 
exchange of the culture medium every 3 days, cultures were maintained for 2 weeks. Then, 
cells were harvested by the use of 0.1% trypsin and 0.04% EDTA for 6 min at 37 °C and 
replated at a density of 1.5 x 104 cells/cm2. Medium was changed every 2 days, and cells at 
passage 6 were used for the study.  
 
3.2.2. Phenotypic characterization of stem cell cultures 
Cells harvested by treatment with 0.1% trypsin and 0.04% EDTA were fixed in 4% 
paraformaldehyde for 20 min, washed with PBS, then resuspended in PBS containing 0.1% 
bovine serum albumin. Typically, 105 cells were incubated in 100 µl solution for 20 min on 
ice with monoclonal antibody followed by two washes in PBS containing 0.1% bovine serum 
albumin and, when necessary, a further incubation with conjugated secondary antibody for 20 
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min at room temperature was performed. Fluorescein isothiocyanate-conjugated monoclonal 
antibodies against hCD34, hCD44 (Immunotech, Marseille, France), unconjugated 
monoclonal antibodies against hCD73, hCD90 (BD Pharmigen), and hCD105 
(DakoCytomation, Glostrup, Denmark), and secondary fluorescein isothiocyanate-conjugated 
sheep F(ab′)2 fragment antimouse immunoglobulin G antibody (Chemicon International, 
Milano, Italy) were used (Mancuso et al., 2009; Pittenger et al., 1999). Flow cytometry was 
performed on a fluorescence-activated cell sorter (BD FACSCalibur, BD Biosciences, 
Franklin Lakes, NJ, USA). CellQuest Pro was the software used for flow cytometry data 
analysis (BD Bioscience, CA, USA). 
 
3.2.3. Determination of doubling time 
The ICCVAM Test Methods Evaluation Report (ICCVAM, 2006b) recommends to use a 
mammalian cell line (or primary cells) that divides rapidly with doubling times of less than 
30 h under standard culture conditions. Human MSCs were plated in 20 Petri dishes (8 cm2, 
Corning, Corning, NY, USA) at a density of 1 x 104 cells/cm2 and incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 in a complete culture medium supplemented with 
20% fetal bovine serum. Cells from three plates were harvested after 5, 24, 48 and 72 h 
respectively, with the use of 0.1% trypsin and 0.04% EDTA for 7 min at 37 °C. Action of 
trypsin was stopped using the complete medium, and Petri dishes were washed with PBS. 
Cells were counted electronically using a Coulter Counter (Beckman Dickinson, Fullertan, 
CA, USA). Under these conditions the approximate doubling time for hMSCs is 24 h.  
 
3.2.4. Chemicals and preparation 
Test materials used for hMSCs NRU assay were purchased from Sigma–Aldrich (St. Louis, 
MO, USA). As suggested by ICCVAM, twelve of the thirty reference substances were 
chosen, two for each of the five GHS hazard categories and two unclassified ones (ICCVAM, 
2006b). As positive control, sodium dodecyl sulfate was used. Chosen chemicals are reported 
in Table 3.1.  
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Table 3.1. The twelve of the thirty ICCVAM reference substances chosen for the study, 
divided for GHS hazard categories, along with the corresponding molecular weight and 
CAS-number. 
 
Chemicals Molecular weight CAS-number 
positive control 
Sodium dodecyl sulfate 288.38 151-21-3 
LD50≤5 mg/kg (class 1) 
Mercury II chloride 271.5 7487-94-7 
Cycloheximide 281.39 66-81-9 
5<LD50≤50 mg/kg (class 2) 
Sodium arsenite 129.91 7784-46-5 
Sodium dichromate dihydrate 298 7789-12-0 
50<LD50≤300 mg/kg (class 3) 
Cadmium II chloride 183.32 10108-64-2 
Sodium fluoride 41.99 7681-49-4 
300<LD50≤2000 mg/kg (class 4) 
Propranolol HCl 295.8 3506-09-0 
Atropine sulfate monohydrate 694.83 5908-99-6 
2000<LD50≤5000 mg/kg (class 5) 
Potassium chloride 74.56 7447-40-7 
Trichloroacetic acid 163.39 76-03-9 
LD50>5000 mg/kg – unclassified (class 6) 
Sodium hypochlorite 74,443 7681-52-9 
Glycerol 92,09 56-81-5 
 
 
3.2.5. Mesenchymal Stem Cells NRU assay 
The NRU assay was performed according to the standard protocol of Borenfreund and 
Puerner (1985) modified by ICCVAM (2006a, 2006b). Human MSCs at 6th passage were 
seeded in 96-well microtiter plates at the concentration of 3.5 x 103 cells/100µl/well in 
αMEM culture medium (supplemented with 20% FBS, 1% penicillin/streptomycin and 2 mM 
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L-glutamine, Sigma), and then were incubated (37 °C/5% CO2) for 24 h, in order to assure 
adequate cell recovery and adherence. This optimal seeding density was determined by 
performing the NRU assay with different cell densities (1.5, 2, 2.5, 3, 3.5, 4, and 4.5 x 103 
cells) in order to identify the number of cells that would allow an exponential growth during 
the test. 
After the 24 h-incubation, cells were treated with eight concentration levels of each test 
chemical in 100 µl treatment medium (αMEM supplemented with 5% FBS, 1% 
penicillin/streptomycin and 2 mM L-glutamine, Sigma). All chemicals were dissolved in 
αMEM culture medium without any solvent, and consequently the untreated vehicle control 
was incubated with only treatment medium. Cells were then incubated (37 °C/5% CO2 ) for 
48 more hours. After the incubation period, the chemical solutions were removed from all 
plates and the cells were washed with 250 µl/well of pre-warmed PBS. After that, 250 µl of 
NR medium (1 ml NR Stock Solution, 79 ml αMEM; Stock Solution: 0.4 g NR Dye, 100 ml 
milliQ H2O) were added to all wells, including the blanks, and incubated for 3 more hours. 
The cells were briefly observed between 2 and 3 h after incubation in order to check the NR 
crystal formation. After 3 h, the NR medium was removed and the cells were carefully rinsed 
with 250 µl/well of pre-warmed PBS. The PBS was discarded and 100 µl/well of NR 
desorbing fixative (1% glacial acetic acid solution, 50% ethanol, 49% H2O) was added, in 
order to elute the dye. Plates were shaken for 20 min to form a homogenous solution and NR 
absorption was detected at 540 nm in a microtiter plate reader/spectrophotometer (BioTek 
EL800 plate reader, BioTek Instrument Inc, Winooski, VT, USA). 
 
3.2.6. Statistical analysis 
Data from the microtiter plate reader were transferred in a spreadsheet template Microsoft 
Office Excell 2007® to determine cell viability (expressed as percentage of untreated 
controls) and to verify the test acceptance criteria established by ICCVAM for the assay 
(ICCVAM, 2006b). Specifically, IC50 values for each test substance were calculated 
according to ICCVAM using the following rearranged Hill function, i.e. a four-parameter 
logistic mathematical model, by means of GraphPad Prism® 4.0 statistical software: 
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                                                                  (1) 
where IC50 is the concentration producing 50% toxicity, EC50 is the concentration producing 
a response midway between the Top and Bottom responses, Top is the maximum response 
(maximum survival), which has been fixed equal to 100, Bottom is the minimum response 
(maximum toxicity), which has been fixed equal to zero when 0% viability is reached during 
the experiments or it is left unconstrained when dose-responses do not achieve 100% 
cytotoxicity, Y = 50 (i.e. 50% response), and HillSlope, which has no units, describes the 
steepness of the curve. To evaluate the capability of the rearranged Hill function to 
quantitatively interpret the experimental data, the determination coefficient R2 was used. 
It should be noted that Eq. (1) is adopted according to ICCVAM (2006a, 2006b), where the 
rearranged Hill function is recommended as the most common equation for in vitro dose-
response data, since all the dose-response information, rather than few points around the IC50, 
is used. Specifically, using the rearranged Hill function it is possible to evaluate the slope of 
the dose-response curve, which is extremely important in predicting the toxicity of a 
substance at specific dose levels, and it shows how fast the response increases as the 
concentration is augmented.  
The obtained IC50 data were reported in terms of their average value ± SD of at least two 
independent experiments, which were carried out in six replicates (i.e. twelve values for each 
substance). The same data were used to perform a linear regression analysis using the 
corresponding LD50 values provided in the ICCVAM Test Methods Evaluation Report 
(ICCVAM, 2006b). To quantitatively evaluate the performed regression analysis, the linear 
determination coefficient r2 was used. The resulting regression was then compared to the 3T3 
and NHK NRU regression ones, through a F-test performed using GraphPad Prism® 4.0 
statistical software. The obtained IC50 data were also used to predict LD50 values and GHS 
hazard categories using the RC rat-only millimole regression and the RC rat-only weight 
regression, as recommended by ICCVAM (2006b). 
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3.3. Results 
Phenotypic characterization of human bone marrow stem cells is considered first. Cells at 
passage six resulted to be negative for CD34 and CD45, and positive for CD44, CD105, 
CD90 and CD73 (data not shown). On the basis of these results, the adopted human bone 
marrow stem cells displayed a mesenchymal phenotype.  
We have been then following the procedure for evaluating the potential use of hMSCs to 
estimate LD50 values and to predict the GHS hazard category for each tested chemical. 
The hMSCs test evaluation was performed using the twelve substances chosen as suggested 
by ICCVAM (2006b) and the cell viability related to each chemical was evaluated following 
the NRU assay. Recommendations from ICCVAM were accurately followed and the 
suggested acceptance criteria were completely fulfilled, otherwise the results were not taken 
into account and the assay was discarded. Such criteria are reported as follows: 
- The average of the left and the average of the right columns of vehicle controls (VCs) do 
not differ by more than 15% from the average of all VCs. 
- At least one calculated cytotoxicity value >0% and ≤50% viability and at least one 
calculated cytotoxicity value >50% and <100% viability must be present. 
- The positive control (SDS) IC50 must be within ± 2.5 standard deviations (SD) of the 
average values established by the laboratory.  
- The positive control (SDS) dose response must have an R2 ≥0.85 for the rearranged Hill 
model fit. 
The concentration of each test chemical reflecting the 50% inhibition of cell viability (IC50) 
was determined from the concentration response data through Eq. (1), as previously described 
in the Section 3.2.6. An example of the fit of the concentration-response data using Eq. (1) is 
shown in Figure 3.1.  
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Figure 3.1. Cell viability data. The cadmium II chloride dose-response curve for hMSCs after 
48 h exposure. Points and error bars show the means ± SD, for the percent cell viability 
response of the 12 replicate wells at each of the eight concentrations. The line shows the fit of 
the concentration-response to the rearranged Hill function, reported in Eq. (1). The IC50 
found was 386.55 ng/ml.  
 
 
 
The obtained IC50 values (expressed as geometric mean) are reported in Table 3.2, along with 
the corresponding values of the rearranged Hill function determination coefficient (R2). Each 
IC50 value was then transformed to mM units, and consequently linearly correlated with the 
corresponding LD50 one from the RC (also reported in Table 3.2). The resulting regression 
was compared with the ones obtained during the 3T3 and NHK ICCVAM Validation Study 
for the same substances, as suggested by ICCVAM (2006b).  
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Table 3.2. Selected chemicals for candidate cytotoxicity test, rodent oral LD50 values from 
the RC (Registry of Cytotoxicity) and IC50 values obtained from our study with hMSCs 
expressed both in µg/ml and mmol/l, with the corresponding values of the rearranged Hill 
function determination coefficient (R2) obtained when fitting viability data for each chemical 
as a function of its concentration levels through Eq. (1). (The IC50 values for SDS represent 
the average of 20 different experiments previously determined in our laboratory). 
 
Chemicals 
RC rodent oral 
LD50 (mmole/kg) 
IC50 (µg/ml) IC50 (mM)  R2 
Sodium dodecyl sulfate 4.4663 53.85 0.19 0.96 
Mercury II chloride 0.0037 43.10 0.16 0.97 
Cycloheximide 0.0071 1.72 0.006 0.96 
Sodium arsenite 0.3156 1.52 0.01 0.89 
Sodium dichromate dihydrate 0.1908 1.15 0.004 0.95 
Cadmium II chloride 0.4801 0.39 0.002 0.98 
Sodium fluoride 4.29 65.51 1.56 0.98 
Propranolol HCl 1.589 22.99 0.08 0.98 
Atropine sulfate monohydrate 0.9204 445.14 0.64 0.98 
Potassium chloride 34.9 5592.89 75.01 0.92 
Trichloroacetic acid 30.59 1408.43 8.62 0.89 
Sodium hypochlorite 138.7 1601.40 21.51 0.91 
Glycerol 137.8 68391.33 742.66 0.98 
 
The obtained regression line and its comparison with both the validated regressions are 
shown in Figure 3.2. F-test was then performed by comparing slopes and intercepts of the 
three regression lines. A significant level of p < 0.05 was used to test whether regressions 
were significantly different from one another, and the results show that hMSCs regression 
line is not statistically different from both 3T3 (slope p value = 0.8231, intercept p value = 
0.4834) and NHK (slope p value = 0.7445, intercept p value = 0.5095).  
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Figure 3.2. Comparison of hMSCs, 3T3 and NHK regressions. hMSCs regression for the 
twelve chosen substances compared to both 3T3 and NHK regressions from the ICCVAM 
Validation Study. The hMSCs regression (black dashed line vs open squares) for twelve 
substances is log LD50 = 0.66 log IC50 + 0.3929 (r2 = 0.6303). The 3T3 regression (black 
dotted line vs open triangles) is log LD50 = 0.7052 log IC50 + 0.6644 for the same twelve 
substances (r2 = 0.7744). The NHK regression (black line vs open circles) is log LD50 = 
0.7246 log IC50 + 0.6534 for the same twelve substances (r2 = 0.8024). The symbol r2 refers 
to the linear determination coefficient. Data for 3T3 and NHK regressions came from the 
ICCVAM Validation Study. 
 
According to the ICCVAM study (2006b), the accuracy of the NRU method and the 
associated IC50 - LD50 regressions can be assessed by calculating the predicted LD50 for each 
tested substance using its geometric mean IC50 in the following regressions, i.e. the RC rat-
only millimole and the RC-rat only weight ones, respectively: 
• log LD50 (mmol/kg) = 0.439 log IC50 (mM) + 0.621. 
• log LD50 (mg/kg) = 0.372 log IC50 (µg/ml) + 2.024. 
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The LD50 values obtained from the regression analyses are reported in Table 3.3 and are then 
used to predict GHS hazard categories, which are shown in Table 3.1 and also included in 
Table 3.3.  
 
Table 3.3. Prediction of GHS Acute Oral Toxicity Category by the hMSCs, 3T3 and NHK 
NRU Test Methods with the RC Rat-Only Millimole and the RC rat-only weight 
regressions. Predictions for hMSCs were calculated in the present study, while 3T3 and NHK 
values come from the ICCVAM Validation Study (a – underprediction, b – overprediction). 
 
Chemicals GHS class 
RC rodent  
oral LD50 
(mg/kg) 
Predicted LD50 (mg/kg) 
with RC Rat-Only 
Millimole Regression 
Predicted LD50 (mg/kg) 
with RC Rat-Only  
Weight Regression 
hMSCs 3T3 NHK hMSCs 3T3 NHK 
Mercury II chloride 
LD50≤5 mg/kg 
(class 1) 1 506
a 181a 209a 429a 179a 203a 
Cycloheximide 
LD50≤5 mg/kg 
(class 1) 2 125
a 48a 33a 129a 57a 40a 
Sodium arsenite 
5 <LD50≤50 mg/kg 
(class 2) 41 77
a 57a 46 123a 95a 80a 
Sodium dichromate 
dihydrate 
5 <LD50≤50 mg/kg 
(class 2) 50 109
a 81a 88a 111a 87a 93a 
Cadmium II chloride 
50 <LD50≤300 mg/kg 
(class 3) 88 51 58 101 74 83 131 
Sodium fluoride 
50 <LD50≤300 mg/kg 
(class 3) 180 213 230 188 501
a 534a 449a 
Propranolol HCl 
300 <LD50≤2000 mg/kg 
(class 4) 470 403 325 492 339 283
b
 402 
Atropine sulfate 
monohydrate 
300 <LD50≤2000 mg/kg 
(class 4) 639 2388
a 1099 1135 1022 529 544 
Potassium chloride 
2000 <LD50≤5000 mg/kg 
(class 5) 2602 2073 1699
b
 1387b 2619 2213 1862b 
Trichloroacetic acid 
2000 <LD50≤5000 mg/kg 
(class 5) 4999 1758
b 1445b 1026b 1568b 1328b 994b 
Sodium hypochlorite 
LD50 >5000 mg/kg 
(class 6) 10328 1196
b 990b 1163b 1645b 1401b 1606b 
Glycerol 
LD50 >5000 mg/kg 
(class 6) 12691 7006 4452
b
 4482b 6647 4526b 4553b 
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Using the RC rat-only millimole regression, it is seen that the hMSCs test method correctly 
predicts the GHS category by 41.7% (5/12) of the tested chemicals, while the 3T3 NRU one 
by 33.3% (4/12) and the NHK one by 41.7% (5/12) respectively. More specifically, in vivo 
toxicity was underpredicted by 41.7%, 33.3% and 25% and overpredicted by 16.7%, 33.3% 
and 33.3% for the hMSCs, 3T3 and NHK, respectively. On the other hand, using the RC rat-
only weight regression, it is seen that the hMSCs test method correctly predicts the GHS 
category by 41.7% (5/12) of the tested chemicals, while both the 3T3 and NHK NRU ones by 
25% (3/12). In vivo toxicity in this case was underpredicted for all the cell lines by 41.7%, 
and it was overpredicted by 16.7%, 33.3% and 33.3% for the hMSCs, 3T3 and NHK, 
respectively. The major difficulty for hMSCs in predicting the right category, using both the 
RC rat-only regressions, was found particularly when considering the most toxic chemicals 
(GHS 1 and 2 classes), whose in vivo toxicity was invariably underpredicted. The same result 
holds also true for the first two GHS classes when considering the 3T3 and NHK NRU assays 
with both the RC rat-only regressions. On the contrary, the use of hMSCs allows one to 
overpredict the in vivo toxicity of only two of the selected chemicals, i.e. trichloroacetic acid 
(GHS class 5) and sodium hypochlorite (GHS class 6). Instead, the 3T3 and NHK validated 
methods resulted in an overprediction for all the slightly toxic chemicals. It should be noted 
that the 3T3 NRU method showed a good prediction only for the case of potassium chloride 
(GHS class 5) when using specifically the RC rat-only weight regression. 
 
3.4. Discussion 
The aim of the present study was to test a new cell line (hMSCs) for basal cytotoxicity 
assays. The approach was based on the regression model developed by Spielmann (1999), 
following the rules established by ICCVAM (2006b) after the 3T3 and NHK Validation 
Study. Recommendations from ICCVAM were accurately followed and the suggested 
acceptance criteria were completely fulfilled. The ICCVAM recommendations require that 
any new cell line to be tested should be demonstrated to meet or exceed the accuracy and 
reliability of the two already validated cell lines 3T3 and NHK. Our results show that the 
obtained hMSCs regression does not differ statistically from the regressions related to 3T3 
and NHK cells validated by ICCVAM, based on the comparison of the slope and the 
intercept, which are essential when considering the test suitable for basal cytotoxicity assays.  
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The accuracy of the presented method was then characterized by identifying the chemicals 
(and their proportion with respect to all tested ones) for which the GHS hazard category was 
correctly predicted, while comparing the proposed cell line to the two validated ones. The 
results clearly show that, for the tested substances, hMSCs have the same or better ability 
than 3T3 and NHK to correctly predict the GHS hazard category.  
This finding seems to be very promising, since the ability to test chemicals using a human 
system would increase the relevance and accuracy of predicting toxicological outcomes. 
Moreover, and that is why we choose to test stem cells, the ability of stem cells to 
differentiate into a variety of cell types and develop into organ system could allow them to 
replace transformed cell lines and primary cells for in vitro studies, thus eliminating potential 
limitations and improving the relevance of predictive assay. Another factor to be considered 
is that the ability to derive stem cells from individual human subjects would offer 
unprecedented opportunities to analyze the contribution of genetic background that affect 
susceptibility to toxicity. 
There are also additional aspects why hMSCs could be a better option than the two already 
validated cell lines. In this regard, it should be pointed out that 3T3 and NHK NRU methods 
are comparable, while the ICCVAM suggests the use of 3T3 cells to conduct these kinds of 
tests because of the lower costs compared to the use of NHK cells. On the other hand, 3T3 do 
not represent a human system that in general should be preferred. Along these lines, hMSCs 
might represent an ideal alternative to NHK, since the corresponding costs of related 
experiments are comparable to 3T3. 
The proposed method will enable toxicity evaluation of novel chemicals in in vitro studies, 
and could also be used for predicting starting doses for in vivo toxicity studies, so that a 
substantial reduction of tested animals and experiment costs will result as well. Such starting 
doses can be effectively employed in the framework of several approved procedures for in 
vivo acute oral toxicity testing, such as ATC (Acute Toxic Class), UDP (Up-and-Down 
Procedure) and FDP (Fixed Dose Procedure) methods, according to OECD (2001a, 2001b, 
2008). In addition, computer simulations could be used appropriately to estimate, per 
substance, the number of animals necessary for the study and also the related survival rate. 
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It should be noted, however, that the proposed cell line, i.e. hMSCs, as well as 3T3 and NHK, 
are not able to correctly predict the right hazard category of the most toxic chemicals (GHS 1 
and 2 classes).  
A number of factors could be potentially responsible for such lack of accuracy. It is apparent 
in this regard that in vitro cell cultures are not able to mimic the kinetics and dynamics of 
substances related to an in vivo system. Indeed, when considering in vitro systems, 
absorption, distribution, metabolism and excretion processes, which control the exposure of 
the target tissue of the organism in vivo, are absent (Blaauboer et al, 1990; Flint, 1990). As a 
consequence, the toxicant concentrations to which in vitro and in vivo systems are exposed 
may not correspond (or correspond only for a limited fraction of time) to each other 
(Blaauboer, 2002a, 2002b; ICCVAM 2006a, 2006b). Thus, as for the chemicals requiring 
metabolic activation to display their toxicity, it is quite possible that their behavior is not 
correctly interpreted by the regression, which in turn is not able to properly predict in vivo 
toxicity (Clemedson et al., 2002).  
Furthermore, it is well known that most basal cytotoxicity assays underestimate toxicity for 
chemicals known to act on specific receptor or cells (Clemedson, et al., 2002). This could be 
the case of mercury II chloride (GHS 1 class) and sodium arsenite (GHS 2 class), whose 
primary target organs in humans are kidney, central, and peripheral nervous systems 
(Aschner and Aschner, 1990; Cheng et al., 2011; HSDB, 2005; Huang et al., 2010; Lewis, 
2000; Magos and Clarkson, 2006) and gastrointestinal tract, heart, brain, and kidneys (Das et 
al., 2010; Garcia-Chavez et al., 2003; HSDB, 2003; Lin et al., 2007; Manna et al., 2008), 
respectively, while the cell lines, i.e. hMSCs as well as 3T3 and NHK, used for toxicity 
assays and compared in this work, are derived from tissues different from the target ones. 
Thus, the toxicity estimated using those cell lines may be ascribed to different mechanisms.  
Another important factor to be considered is the presence of serum proteins, which may or 
may not be included in cell culture systems. For example, hMSCs and 3T3 culture media 
contain serum, while this is not the case of NHK one. Indeed, a toxicant may or may not be 
bound to serum proteins, which could reduce its availability to target sites. Serum proteins 
create an optimal growth environment for the cells and preserve certain vital components, 
such as for example membrane and cytoskeletal ones, or key enzymes. Specifically, the 
underpredicted toxicity of the cycloheximide, a known inhibitor of protein synthesis, could be 
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explained, as supported by Geier et al. (1992), who demonstrated that, although total protein 
synthesis remain blocked, serum inhibits cell death induced by such toxicant, probably 
through stabilization of some crucial cell proteins vital for the cells. 
Let us consider the case when the proposed hMSCs give rise to overpredicted toxicity. While 
certain factors discussed above may have an influence, the observed behavior can be related 
to the NRU assay itself, since it is based on the ability of viable cells to incorporate and bind 
the neutral red, which is a supravital dye that penetrate cell membranes of viable cells and 
accumulates in the lysosomes. Thus, if alterations of the cell surface or the sensitive 
lysosomal membrane due to the action of the toxicant result in a decreased uptake and 
binding of neutral red, a false reflection of low cell number and viability may be observed, 
which in turn gives rise to a toxicity overestimation (Barile, et al., 1994). This explanation 
does apply to the case of trichloroacetic acid, since a recent study shows that it can cause 
lysosomal membrane destabilization (Abdel-Hamid, et al., 2011). Sodium hypochlorite 
behavior as well may be justified, in our opinion, following the same considerations, since it 
displays mechanism of membrane degradation, mainly due to the chlorine action (Estrela et 
al., 2002; Simon et al., 2009).  
In conclusion, we show for the first time that hMSCs can confidently be used to perform in 
vitro acute toxicity tests. Indeed, compared to traditional in vitro systems based on 
transformed or immortalized cell lines, hMSCs provide a more accurate modeling of in vivo 
conditions. It is expected that the study carried out in this research, even if on a relatively 
small number of toxicants, will be a step forward to current and future validation efforts to 
develop alternative methods to replace animal testing. 
 
 
 
 
 
 
 
94 
 
Chapter 4  
Evaluation of ovine blood vessels as a 
possible alternative method for vascular 
toxicity: decellularization 
 
4.1. Introduction  
Heart and blood vessels are an important circuit inside the body both for the transport of 
nutrient and oxygen, through blood delivery, to all the cells of the organism, and for the 
removal of waste products of cellular metabolism from those cells. In serving circulatory 
functions, however, cells of the heart and vasculature are repeatedly exposed to blood-borne 
toxicants and their metabolic products as well, which compromise not only cardiovascular 
function, but interfere with specialized functions as well. What happened is that acute 
cardiovascular toxicity caused by chemicals and drugs involves cellular death and destruction 
of extracellular matrix (ECM) components, and it may also cause alterations of arterial 
pressure, mainly due to changes in contractility and blood flow, finally leading to an end-
organ dysfunction (Partridge et al., 2005). That means that, as a consequence, damages to the 
cells of the heart and vasculature produced by chemicals are reported to be responsible also 
for other organ alterations, such as kidney (Kahan, 1989; Milner et al., 1991) or lung (Martin 
and Kachel, 1987; Martin et al., 1985; Rosenow et al., 1968; White et al., 1989) for example, 
which are highly vascularized (Chappey et al., 1995). Moreover, they can contribute to a 
variety of diseases that today represent a serious threat to human health, including elevated 
blood pressure (hypertension), hardening of the arteries (arteriosclerosis), abnormal heartbeat 
(cardiac arrhythmia), and decreased blood flow to the heart (coronary ischemia) (Laverty et 
al., 2011). That is why studying cardiovascular toxicity, virtually associated directly or 
indirectly with all chemicals and drugs that cause deteriorating effects in mammalian system, 
is so much important, and its accurate understanding and detection is vital both for the 
safeguard of the health of patients and for the development of new drugs and chemicals, 
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being therefore a critical issue in clinical practice, environmental health and drug 
development (Acosta, 2008; Knapton et al, 2010; Laverty et al., 2011). 
In vitro technologies to study chemically-induced injury to the vascular systems cover a wide 
range of possibilities, such as perfused organ preparations (Crass et al., 1988; Hale and 
Poklis, 1986; Hein and Kuo, 1998; Khatter et al., 1989; Pilcher and Langley, 1986; 
Skrzypiec-Spring et al, 2007; Sutherland and Hearse, 2000), organ culture (Bachlav et al., 
1999; De lima et al., 1999; Gotlieb and Boden, 1984; Ingwall et al., 1975; Speralakis and 
Shigenoubu, 1974, Tanaka et al., 1987), tissue slices (Gandolfi et al., 1995; Kretz et al., 
2002; Parrish et al., 1995), isolated muscle preparations (Abdel-Haq et al., 2000; Campbell et 
al., 2000; Conklin and Boor, 1998; Koyama et al., 1997; Togna et al., 1984), or cell 
suspensions (Andrieu-Abadie et al., 1999; Khalifa et al., 1991; Shyu et al., 2000) and 
cultures (Aszalos et al., 1984; Concklin et al., 1999; Estevex et al., 2000; He et al., 1999; 
Hendrickson et al., 1999; Kossenjans et al., 1996; Marra et al., 2000; Muthalif et al., 2001; 
Parrish and Ramos, 1997; Ramos et al., 1984; Wenzel and Innis, 1983), depending on what is 
the objective to be tested. Clearly, responses at the cellular level may be not representative of 
those observed in the intact organism and therefore multiple approaches need to be employed 
to properly assess the overall toxic response (Partidge et al, 2005). Common in vitro models 
for evaluating cardiovascular toxicity are listed in Table 4.1, as provided by Partidge et al. 
(2005).  
What interests us the most with regard to our studies is specifically "vascular toxicity", 
therefore the toxicity of the vasculature, and the application of those models considering 
whole perfused blood vessels. The use of such preparations in toxicological studies is 
advantageous because the level of structural organization is similar to that encountered in 
vivo, and changes in physiological or pharmacological sensitivity, excitability and 
contractility can be readily evaluated. On the contrary, their most significant limitations are 
the small number of replicate preparations that can be processed at any time, and the short 
time available for isolation and placement of the tissue under physiological conditions 
(Partidge et al, 2005). We therefore thought about a model able to get through these 
limitations, while maintaining all the advantages the most as possible. In our opinion, the 
application of tissue engineering principles, which hold today great promises in several fields, 
and of the concepts of decellularization/recellularization could be applied to this matter. 
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Table 4.1. Common in vitro models for evaluating cardiovascular toxicity. 
 
 
Several groups today focus their studies on the decellularization of tissues and organs (Bader 
et al., 1998; Badylak et al., 1989, 1995; Booth et al., 2002; Chen et al., 1999, 2004; Cortiella 
et al., 2010; Freytes et al., 2004; Gilbert et al., 2005; Grauss et al., 2005; Kasimir et al., 
2003; Korossis et al., 2002; Kropp et al., 1995; Ott et al., 2008; Petersen et al., 2010; Rieder 
et al., 2004; Schenke-Layland et al., 2003; Taylor, 2009; Uygun et al., 2010; Wainwright et 
al., 2010), including blood vessels (Conklin et al., 2002; Dahl et al., 2003; Schmidt et al., 
2000; Uchimura et al., 2003), in order to obtain matrices for tissue engineering, providing a 
high number of quite different protocols and cover a wide range of techniques (Badylak et 
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al., 2011; Crapo et al., 2011). The term "decellularization" refers to a series of methods by 
which the cellular membrane surrounding an isolated organ, or at least a part of it, is removed 
and the cytoplasmic and nuclear components are solubilised, leaving the complex mixture of 
structural and functional proteins that constitute the ECM intact, so minimizing any adverse 
effect on its composition, biological activity, and mechanical integrity. A decellularization 
protocol generally begins with the lysis of the cell membrane using physical treatments or 
ionic solutions, it is followed by separation of cellular components from the ECM using 
enzymatic treatments, solubilisation of cytoplasmic and nuclear cellular components using 
other detergents, and finally removal of cellular debris and residual chemicals from the tissue. 
All of these steps can be coupled with mechanical agitation to increase their effectiveness 
(Crapo et al., 2011; Gilbert et al., 2006). On the contrary, "recellularization" (or 
repopulation) refers to a regeneration process which occurs by contacting a decellularized 
organ or tissue (essentially the biological scaffold) with a population of regenerative cells 
(e.g. stem cells, either undifferentiated, partially or fully differentiated). These cells can be 
introduced (seeded) into the scaffold either by perfusion or, alternatively or in addition, by 
injection into one or more locations and at different densities depending on organ/tissue size 
(Badylak et al., 2011; Ott and Taylor, 2007). 
On the basis of these concepts, the path we aim to follow is decellularizing blood vessels, 
taken from animals at the local abattoir, in order to obtain suitable biological scaffolds, and 
recellularize them with human mesenchymal stem cells harvested from human bone marrow, 
in order to obtain a vessel which could be the most as possible comparable to a human one. 
Then, the idea is to set up a novel human toxicity test, based on perfusion, for different 
substances, as requested by the REACH Regulation. From our best knowledge, indeed, this 
kind of approach has never been used for the evaluation of in vitro vascular toxicity, and 
could have several advantages for increasing knowledge in this field, while at the same time 
it seems to be in line with the very important concepts of improving alternative methods and 
of refinement, reduction and replacement of animal models. For the moment, only the first 
part of the project, i.e. the decellularization process, has been performed, and the 
corresponding results we obtained from histological examination of different protocols 
brought us to find a robust and effective method of decellularization, as reported in what 
follows. 
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4.2. Material and methods  
4.2.1. Artery preparations 
Descending and abdominal tracts of aorta samples from adult sheep were obtained from a 
local abattoir (CO.AL.BE. dei F.lli Contu & C.s.n.c., Cagliari, Italy). Tissue was immediately 
transported to the laboratory on ice, being careful that the warm ischemic time was no more 
than 1 h from the time of tissue extraction to processing or storage at -20°C. Aorta samples, 
after arriving at the laboratory, were always cleaned from fat and adherent tissue with a 
scalpel, and samples of approximately 2.5 cm in length were prepared, considering vessels 
with an internal diameter of 0.8-1 cm (cf. Figure 4.1). Artery segments were immediately 
washed for about 30 minutes at +4°C in a PBS solution (PBS, Sigma, St. Louis, MO, USA) 
containing 1% penicillin/streptomycin (Sigma), in order to avoid the risk of bacterial 
contamination. After that different kinds of treatments were performed.  
 
4.2.2. Decellularization protocols 
Different kinds of treatments, testing several substances alone and/or in suitable combination 
and varying the contact time, always at Room Temperature (RT, approximately 25°C) under 
stirring conditions to facilitate cell removal were performed. In all of the performed tests, a 
segment of fresh sample was immediately fixed in formalin to serve as control (CTRL). The 
treatments were always performed in a 100 ml-becker and the amount of solution was 
calculated considering approximately 15 ml per cm of length, in order to completely cover 
the sample. At least three repetitions per type of Protocol were performed independently. 
Protocol A (A1, A2, A3, A4) uses a PBS solution containing 1% SDS (Sodium Dodecyl 
Sulfate, Sigma) for 3-6-12-24 h.  
Protocol B (B1, B2, B3, B4) uses a PBS solution containing 1% Triton X-100 (Sigma) for 3-
6-12-24 h.  
Protocol C uses a PBS solution containing 0.01% Trypsin/EDTA (Sigma) for 24 h.  
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Protocol D uses a PBS solution containing 1% SDS for 6 h, a PBS solution containing 1% 
Triton X-100 for 16 h, and a PBS solution containing 0.01% Trypsin/EDTA for 6 h. 
Protocol E, taken from the literature (Sawa et al., 2005), uses a PBS solution containing 1% 
SDS for 48 h; the samples are then washed in a PBS solution for 24 h, treated in a PBS 
solution containing 1% Triton X-100 for 48 h, and washed again for about 72 h. All the 
solutions were changed every 24 h. Subsequent Protocols F and G were modified from 
Protocol E. 
Protocol F uses a PBS solution containing 1% SDS for 24 h; the samples are then washed in 
a PBS solution for 24 h, treated in a PBS solution containing 1% Triton X-100 for 24 h, and 
washed again for about 72 h. All the solutions were changed every 24 h.  
Protocol G uses a PBS solution containing 1% SDS for 48 h; the samples are then washed in 
a PBS solution for 12 h, treated in a PBS solution containing 1% Triton X-100 for 24 h, and 
washed again for about 48 h. All the solutions were changed every 24 h. 
 
4.2.3. Histological analysis 
Immediately after treatments, samples were fixed in formalin and afterwards dehydrated in an 
ascending series of alcohols, embedded in resin (Technovit 7100, Heraeus Kulzer GmbH & 
Co. KG, Wehrheim, Germany), and sectioned at a thickness of 3.5 µm (LKB 2218 
BROMNA Historange Microtome). Sections were transferred to slides, oven-dried (45°C for 
24 h), and finally stained with Hematoxylin and Eosin staining, Masson’s Trichrome staining, 
Silver Impregnation, Verhoeff and Weigert stainings, depending on the cases. The stained 
sections were then examined under a light microscope (Leica DM IL, Leica Microsystems, 
Germany) for the presence of cell nuclei and for analyzing morphology of collagen and 
elastic fibres. Histological sections were taken from both control and treated samples in each 
decellularization run and compared in order to verify tissue decellularization. 
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Figure 4.1. Aorta samples. (a) and (b) show aorta samples before cleaning procedure from 
fat and adherent tissues; (c) show the samples after the cleaning procedure; (d) shows the 2.5 
cm length sample. 
 
  
  
 
4.3. Results 
Fresh porcine aorta (CTRL) samples showed the typical features of this vessel, with presence 
of cellular nuclei immersed in a matrix of collagen and elastic fibres. Nuclei are evidenced 
with Hematoxylin and Eosin staining (cf. Figure 4.2), while collagen fibres may be seen with 
both Masson's Trichrome staining (cf. Figure 4.3) and Silver Impregnation (cf. Figure 4.4), 
and elastic fibres may be highlighted with both Verhoeff staining (cf. Figure 4.5) and 
Weigert staining (cf. Figure 4.6). 
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Attempt to obtain decellularized scaffolds from ovine arteries were performed by means of 
different treatments, always at RT and under stirring conditions, as reported in the Material 
and Methods paragraph. Of all the tested treatments, only two of them resulted in an effective 
decellularization procedure, based on histological results and comparison with CTRL 
samples. After treatments with Protocols A and B, and under high powered light 
microscopic examination of the Hematoxylin and Eosin-stained specimens, results show that 
the cellular material was not solubilised, and nuclei were still present in the ECM. Therefore, 
these protocols were both considered to be ineffective. Only results from Protocol A are 
shown, because the ones related to Protocol B are essentially the same (cf. Figure 4.7). 
Also Protocol C resulted to be ineffective. Indeed, even after the treatment with 
Trypsin/EDTA and examination with Hematoxylin and Eosin-staining, some of the nuclei 
were still present in the ECM. Moreover, in this case, an altered structure of the ECM 
structure was observed (cf. Figure 4.8). 
On the contrary, Protocol D, after examination of the Hematoxylin and Eosin-stained 
specimens, resulted in a complete absence of nuclei. However, from the different staining 
performed, a clear destruction of the ECM was observed (cf. Figure 4.9), and therefore the 
Protocol is considered to be ineffective as well.  
Literature Protocol E was instead considered to be effective, based on the absence of cellular 
or nucleic components in both the luminal surface and the underlying matrix scaffolding (cf. 
Figure 4.10) after examination of the Hematoxylin and Eosin-stained specimens. The 
staining revealed that the vascular matrices processed with the described decellularization 
technique were indeed all acellular. Moreover, the structure of the ECM resulted well 
preserved. 
Unfortunately, attempts to decrease the time required for Protocol E, i.e. treating samples 
with Protocol F, did not provide successful results, since cellular nuclei were still present 
after the treatment (cf. Figure 4.11). 
Finally, Protocols G was instead considered to be effective, on the same bases reported for 
Protocol E. The matrix resulted to be indeed well preserved and acellular (cf. Figure 4.12). 
102 
 
Further histological analysis were performed for the case of these successful protocols 
(Protocols E and G), thus confirming a well preserved decellularized vascular ECM. It was 
shown indeed that collagen (Masson’s Trichrome Staining, cf. Figure 4.13) and elastic fibres 
(Verhoeff Staining, cf. Figure 4.14) kept their original porous morphology and structure. 
Only results from Protocol G are shown, because those ones related to Protocol E are 
essentially the same. 
 
4.4. Discussion 
The aim of the present study was to find the most effective and least destructive procedure, 
among different protocols, to be used in order to obtain the most as possible preserved 
decellularized matrix from ovine blood vessels (in the specific case aorta). In all the cases, 
sample agitation was guaranteed since, as it is reported in literature, physical methods of that 
type, can increase the effectiveness of the process, facilitating cellular lysis and removal of 
the cell content from the ECM. However, such physical treatments are generally insufficient 
to achieve a complete decellularization, and therefore they must be combined also with 
enzymatic (e.g. trypsin) and chemical ones (e.g. ionic and non ionic solutions or detergents), 
which disrupt cell membranes and the bonds responsible for inter- and extracellular 
connections (Gilbert et al., 2006). For this reason, we performed different kinds of 
treatments, in order to compare the decellularization potential of three of the most used 
decellularization agents, alone and/or in combination under different contact times.  
Firstly, we chose to use an ionic detergent, the Sodium Dodecyl Sulfate, since it results to be 
very effective for removal of cellular components from tissues, even more than other agents. 
Since SDS is an ionic detergent, it solubilizes cytoplasmic and nuclear cellular membranes 
and tends to denature cytoplasmic proteins. We chose to use a non ionic detergent as well, the 
Triton X-100, since such detergents are quite extensively used in these kinds of treatments 
because of their relative mild effects on tissue structure. Lipid-lipid and lipid-protein 
interactions are then disrupted, while leaving protein-protein interactions intact (Crapo et al., 
2011; Gilbert et al., 2006; Seddon et al., 2004). Finally, we performed also enzymatic 
treatments, using Trypsin/EDTA. Trypsin is a proteolytic enzyme that cleaves peptide bonds 
(Voet et al., 2002), while EDTA is a chelating agent that disrupt cell adhesion to ECM, 
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thereby facilitating cell removal, while tending to disrupt the ECM ultrastructure (Gilbert et 
al., 2006; Waldrop et al., 1980).  
The evaluation of the protocol efficiency to verify the removal of cellular material from the 
tissues and also the preservation of the ECM is essential. It can be assessed by several 
methods, including for example histological staining, necessary to examine for the presence 
of nuclei or various cytoplasmic and extracellular molecules, such as collagen, adhesion 
proteins like fibronectin and laminin, GAGs, elastic fibres, etc. Other methods comprise 
immunohistochemistry, to analyze specific intracellular proteins, such as actin and vimentin, 
inspection for the presence of DNA using fluorescent molecules, electron microscopic 
methods to examine the presence of remnant nuclear material or cytoplasmic debris, and also 
mechanical testings for the check of the presence and integrity of structural proteins within 
the scaffold (Crapo et al., 2011; Gilbert et al., 2006). The present study focused on the 
histological analysis of the different applied protocols, using hematoxylin and eosin to firstly 
examine the presence or absence of nuclei, and alternative staining to verify the structure of 
collagen and elastic fibres, which are two of the main components of a blood vessel.  
We can conclude from our results that a combination of different agents is preferable to the 
use of a single one. Indeed, we demonstrated that, in the case of ovine aorta, a treatment with 
a single agent (cf. Protocol A, B and C) do not result in decellularization, since nuclei were 
not removed from the ECM (cf. Figures 4.7 and 4.8).  
Instead of further increasing the time of treatment with each one of the single agents, these 
results drove us to test a protocol that may be considered as a combination of Protocols A, B, 
and C (Protocol D). The reason that brings us to such a choice is that it is probably better to 
combine different agents in order to act simultaneously in different directions and obtain a 
more successful removal of the nuclear material. Even if, after this treatment, the nuclei of 
the cells resulted to be absent, the structure of the ECM, as shown in Figure 4.9, resulted to 
be definitely distorted, compared to the CTRL structure (cf. Figures 4.2, 4.4 and 4.6). Such 
distortion is obviously not acceptable from the decellularization point of view, because its 
goal is indeed the solubilisation of cytoplasmic and nuclear components, while leaving intact 
the complex mixture of structural and functional proteins that constitute the ECM (Gilbert et 
al., 2006). In fact, the final aim of such process is to obtain a biological scaffold to be 
recellularized, and it is known that composition and ultrastructural characteristics of the ECM 
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play an important role in cells’ attachment, thus regulating their ability to migrate into and 
attach to specific locations (Brown et al., 2006), and also influence tissue-specific phenotypic 
differentiation (Badylak et al., 2011; Cortiella et al., 2010; Gong et al., 2008; Sellaro et al., 
2010). In our opinion, the distortion observed in the results could be mainly due to the 
combined presence of Trypsin/EDTA. As already anticipated indeed, Trypsin/EDTA tend to 
disrupt the ECM ultrastructure, affecting ECM proteins such as collagen (Waldrop et al., 
1980), which is one of the main constituents of the matrix (especially in blood vessels) 
(Wagenseil and Mecham, 2009). Such opinion is even supported from results obtained after 
treatment with Protocol C, which is the only other one were Trypsin/EDTA was used. Also 
in this case, indeed, as shown in Figure 4.8, a distortion of the matrix occurred, even on a 
small scale. Based on this conclusion and on the fact that for our further purposes we need to 
obtain a vessel the most as possible similar to an operating one, we decided to avoid the use 
of Trypsin/EDTA, even at lower concentration and for shorter periods of time.  
Successful and effective treatments resulted to be those ones where Protocol E and G were 
applied. Nuclei resulted to be totally absent (cf. Figures 4.10 and 4.12) and the ECM 
structure is much better organized, with fibres (mainly collagen and elastic fibres) more 
linear, regular and close to each other (cf. Figures 4.13, and 4.14). Protocol G was modified 
from Protocol E, which has been taken from the literature (Sawa et al., 2005), in order to 
improve it, while better preserving ECM structure and saving processing time. The obtained 
results were satisfying and encouraging. By cutting by 50% the time required for the action of 
Triton X-100, indeed, an appropriate decellularization was also obtained, with a complete 
solubilisation of the nuclear material. The attempt to decrease by 50% the time required for 
Protocol E (Protocol F), in order to shorter the contact of the detergents with the ECM, was 
unfortunately not successful. We decided, therefore, to cut the time required only by one of 
the used agents. The choice was to consider Triton X-100 because the SDS appears to be 
more effective than Triton X-100 in removing nuclei, while preserving tissue mechanics, 
aspect which is of course essential for blood vessels functioning. Moreover, its addition to a 
decellularization protocol can make the difference between complete and incomplete cell 
nuclei removal (Crapo et al., 2011). Alternative staining demonstrated that Protocol G was 
able to maintain an appropriate ECM structure, both in terms of collagen and elastic fibres 
(cf. Figures 4.13 and 4.14 in comparison with Figures 4.3 and 4.5), and therefore we can 
conclude that, even if further works are required in order to reach the final goal of our study, 
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these results are already quite encouraging and promising, since we have improved quite long 
decellularization protocols in terms of time and costs, thus assuring at the same time a better 
preservation of the extracellular matrix, which is essential for the next steps of the process. 
This decellularized ECM from ovine aorta could be used in a subsequent phase of the study 
as a biological scaffold where seeding human MSCs in order to obtain a vessel which could 
be the most as possible comparable to a human one, and with the final aim of setting up a 
novel in vitro human toxicity test based on perfusion. Our choice to use human MSCs for this 
purpose has to be related to the unique properties of this cell type, such as unlimited 
proliferation ability and being a readily available source of human cells, but mainly because 
of their capability to generate other cell types (Davila et al., 2004; Laustriat et al., 2010; 
Trosko and Chang, 2010; Wobus and Loser, 2011). With regard to blood vessels’ population 
of cells, for example, recent in vitro-studies presented the differentiation ability of MSCs to 
differentiate into cells with an endothelial phenotype as well as into smooth muscle cells 
(Gong and Niklason, 2008; Hashi et al., 2007). Although further studies have to be made for 
completely fulfil the high expectations in this field, MSCs remains very promising and, by 
means of their selective isolation and expansion in vitro and specific stimulation (growth 
factors, culture media, etc.), endothelial and vascular muscle cells can be propagated and 
used for the repopulation of a decellularized vessel (Aper et al., 2009). 
The new in vitro test could then be used for the testing of different substances, as requested 
by the REACH Regulation, being therefore of primary importance and in line with what is 
requested today by the legislation, and in our opinion could have several advantages. Firstly, 
difficulties in obtaining vessels from patients or cadavers would be avoided, enlarging 
therefore the possible number of replicates that could be processed at any time. By taking into 
account the alternative of using animal vessels, the repopulation of the matrix, considered 
merely as a biological scaffold, with human cells would solve the problem of species-specific 
differences, and extrapolation and assumptions, which is one of the main problems arising 
from animal experimentation. However, since discrepancies can arise between in vivo and in 
vitro testing (Bhogal, et al., 2005; Blaauboer, 2002a, 2002b; Flint, 1990; Piersma, 2006; 
Zucco, et al., 2004), experimental animals cannot be avoided at all, as in toxicology testing in 
general, but the proposed method could be considered as a reduction alternative, in line with 
the 3Rs principle proposed by Russel and Burch (1959), since it could serve as a first line of 
inspection and the number of animals required for the tests would be considerably reduced. 
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Moreover, it should be noticed that, the possibility to obtain stem cells from individual 
human subjects and therefore the future possibility of obtain an in vitro vascular system 
which is specific for specific patients, would offer unprecedented opportunities to analyze the 
contribution of genetic background that affects susceptibility to toxicity and particularly 
vascular susceptibility. 
 
Figure 4.2. Hematoxylin and Eosin staining for the CTRL samples. Results from 
Hematoxylin and Eosin staining, which is one of the most common methods used in histology 
and anatomy, confirm the presence of cellular nuclei in CTRL samples. The nuclei of the cells 
are stained blue-purple with Hematoxylin, while eosinophilic structures, such as cytoplasm, 
connective tissue and other extracellular substances are counterstained bright pink with 
Eosin. Different magnifications are shown.  
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Figure 4.3. Masson's Trichrome staining for the CTRL samples. Results from Masson's 
Trichrome staining, a three-color staining protocol commonly used in histology for the 
detection of fibres in tissues, confirm the typical features of CTRL samples. Collagen fibres 
are stained blue, while nuclei are stained dark purple and the background - acidophilic 
cytoplasm and muscle fibres - is stained pink. Different magnifications are shown. 
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Figure 4.4. Silver impregnation for the CTRL samples. Results from Silver Impregnation, 
another staining protocol commonly used in histology for the detection of fibres in tissues, 
confirm the typical features of CTRL samples. Fibrillar collagen, which represents the 
structural support for cells, is stained in yellow, while reticular fibres, the more immature 
form of the collagen, are stained in black. Different magnifications are shown. 
  
 
 
Figure 4.5. Verhoeff staining for the CTRL samples. Results from Verhoeff staining, a 
technique used to detect elastic fibres in tissues, confirm their typical features in CTRL 
samples. Elastic fibres are stained in black. Different magnifications are shown. 
  
 
 
109 
 
Figure 4.6. Weigert staining for the CTRL samples. Results from Weigert staining, another 
technique used to detect elastic fibres in tissues, confirm their typical features in CTRL 
samples. Elastic fibres are stained in purple. Different magnifications are shown. 
  
 
 
 
Figure 4.7. Hematoxylin and Eosin staining for the Protocol A-treated samples. Results 
show that the cellular material was not solubilised after treatment with Protocol A, and 
nuclei were still present in the ECM. Nuclei are stained blue-purple. 
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Figure 4.8. Hematoxylin and Eosin staining for the Protocol C-treated samples. Results 
show that after the treatment with Protocol C and examination with Hematoxylin and Eosin-
staining, some of the nuclei (stained in blue) were still present in the ECM, and an altered 
structure of the ECM structure was observed. Different magnifications are shown. 
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Figure 4.9. Different stainings for the Protocol D-treated samples. (a) Hematoxylin and 
Eosin staining; (b) Silver Impregnation; (c) Weigert staining. Results show that the treatment 
with Protocol D resulted in a complete absence of nuclei; however, a clear destruction of the 
ECM was observed. 
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Figure 4.10. Hematoxylin and Eosin staining for the Protocol E-treated samples. Results 
show that the treatment with Protocol E resulted on the absence of cellular or nucleic 
components in both the luminal surface and the underlying matrix, and the structure of the 
ECM resulted well preserved. Different magnifications are shown. 
  
 
 
Figure 4.11. Hematoxylin and Eosin staining for the Protocol F-treated samples. Results 
show that cellular nuclei (stained in blue) were still present after the Protocol F- treatment. 
Different magnifications are shown. 
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Figure 4.12. Hematoxylin and Eosin staining for the Protocol G-treated samples. Results 
show that the treatment with Protocol G resulted on the absence of cellular or nucleic 
components in both the luminal surface and the underlying matrix, and the structure of the 
ECM resulted to be well preserved. Different magnifications are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
Figure 4.13. Masson’s Trichrome Staining for the Protocol G-treated samples. Results 
show that, after the treatment with Protocol G, collagen fibres kept their original morphology 
and structure. 
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Figure 4.14. Verhoeff Staining for the Protocol G-treated samples. Results show that, after 
the treatment with Protocol G, elastic fibres kept their original morphology and structure. 
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Conclusions  
Today, modern society is becoming constantly more dependent on the use of a wide range of 
different chemicals, that provide substantial highly appreciated benefits, but at the same time 
also have the potential to cause damages to the environment and human health. Therefore, in 
order to ensure an adequate protection, it is essential to evaluate their potential to cause 
adverse effects and to provide reliable and adequate information on them through a process 
named risk assessment. Toxicological testing is therefore an important part of the regulatory 
safety assessment for chemicals worldwide. Currently, test methods rely largely on animal 
models, even if the utility of the data obtained with in vivo tests has been often questioned, 
due to scientific, economic and ethical concerns. These factors, together with legislative 
changes (among the others the REACH Regulation), are driving toxicologists to explore the 
potential of non-animal alternative approaches to assess toxicity in the pharmaceutical and 
chemical industries. Recently indeed, many in vitro methods for toxicity testing have been 
developed as alternatives to whole animal tests, according to the 3Rs approach – Refinement, 
Reduction, and Replacement – started in 1959 by Russell and Burch. Clearly, especially 
replacement and/or reduction of unnecessary in vivo tests, that today has reached a high 
priority level and has been heavily promoted, would have significant animal welfare benefits 
and would also result in lower testing costs and time. 
The activity performed during the PhD falls within the framework of the risk assessment of 
industrial/commercial chemicals, and specifically in the REACH Regulation, giving specific 
relevance to the 3Rs concept. It concerns, indeed, the development of novel in vitro models in 
order to test the potential toxicity of drugs and chemicals, following two different lines of 
research, both of them based on the use - for the first time - of human Mesenchymal Stem 
Cells (MSCs) isolated from bone marrow. From our best knowledge indeed, both animal and 
human MSCs have never been adopted for developing in vitro model systems for acute 
toxicity tests, but their unique proprieties, such as unlimited proliferation ability, plasticity to 
generate others cell types and even being a more readily available sources of human cells, 
clearly identify their potential benefits in toxicology. Moreover, they would permit to 
overcome limitations related to ESCs and iPS cells, such has ethical concerns and potentially 
tumorigenic status. 
117 
 
The research activity has been firstly focused on the application of a selected in vitro toxicity 
method, the NRU assay, to detect chemical toxicity on human MSCs. Specifically, the aim of 
this study was to evaluate the applicability of human MSCs as cell line for in vitro 
cytotoxicity tests to correctly predict LD50 and the hazard category of chemicals according to 
the Globally Harmonized System of Classification – GHS. By comparing the behavior of 
MSCs with the already validated 3T3 and NHK NRU test methods (validated by ICCVAM in 
2006), the results clearly show that the tested cell line can confidently be used to perform in 
vitro acute toxicity tests, providing a more accurate modeling of in vivo conditions. Indeed, 
the ability to test chemicals using a human system would increase the relevance and accuracy 
of predicting toxicological outcomes. Moreover, the ability of stem cells to differentiate into 
a variety of cell types and develop into organ system could allow them to replace transformed 
cell lines and primary cells for in vitro studies, thus eliminating potential limitations and 
improving the relevance of predictive assay. Another factor to be considered is that the ability 
to derive stem cells from individual human subjects would offer unprecedented opportunities 
to analyze the contribution of genetic background that affect susceptibility to toxicity. There 
are also additional aspects why human MSCs could be a better option than the two already 
validated cell lines. In this regard, it should be pointed out that 3T3 and NHK NRU methods 
are comparable, while the ICCVAM suggests the use of 3T3 cells to conduct these kinds of 
tests because of the lower costs compared to the use of NHK cells. On the other hand, 3T3 do 
not represent a human system that in general should be preferred. Along these lines, human 
MSCs might represent an ideal alternative to NHK, since the corresponding costs of related 
experiments are comparable to 3T3. Furthermore, the proposed method will enable toxicity 
evaluation of novel chemicals in in vitro studies, and could also be used for predicting 
starting doses for in vivo toxicity studies, so that a substantial reduction of tested animals and 
experiment costs will result as well. For all these reasons, it is expected that the study carried 
out, even if on a relatively small number of toxicants, and even considering that, however, the 
proposed cell line, as well as 3T3 and NHK, is not able to correctly predict the right hazard 
category of the most toxic chemicals (GHS 1 and 2 classes) due to a number of potential 
factors, will be a step forward to current and future validation efforts to develop alternative 
methods to replace animal testing. 
Next, the research activity was mainly focused on the research of new in vitro methods in 
order to test, specifically, the vascular toxicity of chemicals. This research is based on the 
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application of emerging tissue engineering concepts in the field of toxicology. For the 
moment, only preliminary studies were conducted, which regarded the application of 
decellularization techniques to blood vessels harvested from animals at the local abattoir, in 
order to obtain biological scaffolds. These scaffolds could be subsequently used for 
recellularization processes using human MSCs, and setting up of perfused in vitro human 
toxicity tests. Of course, it is necessary to be sure that the animal vessel to be used as scaffold 
is completely acellular. The study presented in this thesis focused, therefore, on the 
histological evaluation of the different decellularization protocols performed, in order to find 
the most effective and least destructive procedure to be used in order to obtain the most as 
possible preserved decellularized matrix from ovine blood vessels (in the specific case aorta). 
Firstly, the samples were subjected to agitation because physical methods, such as agitation, 
can increase the effectiveness of the process, facilitating cellular lysis and removal of the cell 
content from the ECM. However, physical treatments like this are generally insufficient to 
achieve a complete decellularization, and therefore they must be combined also with 
enzymatic (e.g. trypsin) and chemical ones (e.g. ionic and non ionic solutions or detergents), 
which again disrupt cell membranes and the bonds responsible for inter- and extracellular 
connections. Among the different tested protocols, the obtained results let us to conclude that 
an optimized effective protocol has been achieved using a combination of two different 
chemicals, a ionic detergent (SDS) and a non ionic one (Triton X-100). Results show, indeed, 
that after this treatment the scaffold resulted to be completely acellular and an appropriate 
ECM structure was maintained, both in terms of collagen and elastic fibres, characteristics 
that are the goal of the perfect decellularization protocol. Therefore, we can conclude that, 
even if further works are required in order to reach the final goal of our study and setting up a 
new in vitro test for vascular toxicity, these results are already quite satisfying and promising, 
since we have improved a quite long decellularization protocol in terms of time and costs, 
assuring at the same time a better preservation of the extracellular matrix, which is essential 
for the next steps of the process.  
We can generally conclude that the activities performed during this thesis work represent a 
step forward to current and future validation efforts to develop alternative methods to replace 
animal testing, perfectly fitting in one of the most current hot topic in toxicological research 
and being in line with what is today highly required from scientific, economic and ethical 
points of view, as well as from European legislation.  
119 
 
Appendix 1 
Specific References in the Regulation to animal testing 
Alternatives to animal testing are strongly promoted throughout the REACH text. All the 
Regulation recitals and articles where the matter is handled are report in what follows 
(European Parliament, 2006, 2007). 
 
Recital (1). Promotion of the development of Alternative Methods for the assessment of 
hazards of substances. This Regulation should ensure a high level of protection of human 
health and the environment as well as the free movement of substances, on their own, in 
preparations and in articles, while enhancing competitiveness and innovation. This 
Regulation should also promote the development of alternative methods for the assessment of 
hazards of substances.  
 
Recital (13). Cosmetics. This Regulation should apply without prejudice to the prohibitions 
and restrictions laid down in Council Directive 76/768/EEC of 27 July 1976 on the 
approximation of the laws of the Member States relating to cosmetic products in so far as 
substances are used and marketed as cosmetic ingredients and are within the scope of this 
Regulation. A phase-out of testing on vertebrate animals for the purpose of protecting human 
health as specified in Directive 76/768/EEC should take place with regard to the uses of those 
substances in cosmetics.  
 
Recital (33). Joint submission and sharing of information to reduce testing on 
vertebrate animals. Joint submission and the sharing of information on substances should be 
provided for in order to increase the efficiency of the registration system, to reduce costs and 
to reduce testing on vertebrate animals. One of a group of multiple registrants should submit 
information on behalf of the others according to rules which ensure that all the required 
information is submitted, while allowing sharing of the costs burden. A registrant should be 
able to submit information directly to the Agency in certain specified cases.  
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Recital (37). Tests to comply with requirements of protection of laboratory animals 
(86/609/EEC) and GLP (Good laboratory Practice). If tests are performed, they should 
comply with the relevant requirements of protection of laboratory animals, set out in Council 
Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and 
administrative provisions of the Member States regarding the protection of animals used for 
experimental and other scientific purposes, and, in the case of ecotoxicological and 
toxicological tests, good laboratory practice, set out in Directive 2004/10/EC of the European 
Parliament and of the Council of 11 February 2004 on the harmonisation of laws, regulations 
and administrative provisions relating to the application of the principles of good laboratory 
practice and the verification of their application for tests on chemical substances.  
 
Recital (40). Commission, Member States, industry and other stakeholders should 
continue to contribute to promotion of alternative test methods. The Commission, 
Member States, industry and other stakeholders should continue to contribute to the 
promotion of alternative test methods on an international and national level including 
computer supported methodologies, in vitro methodologies, as appropriate, those based on 
toxicogenomics, and other relevant methodologies. The Community's strategy to promote 
alternative test methods is a priority and the Commission should ensure that within its future 
Research Framework Programmes and initiatives such as the Community Action Plan on the 
Protection and Welfare of Animals 2006 to 2010 this remains a priority topic. Participation of 
stakeholders and initiatives involving all interested parties should be sought.  
 
Recital (47). In accordance with Directive 86/609/EEC, it is necessary to replace, reduce, 
and refine testing on vertebrates. In accordance with Directive 86/609/EEC, it is necessary 
to replace, reduce or refine testing on vertebrate animals. Implementation of this Regulation 
should be based on the use of alternative test methods, suitable for the assessment of health 
and environmental hazards of chemicals, wherever possible. The use of animals should be 
avoided by recourse to alternative methods validated by the Commission or international 
bodies, or recognised by the Commission or the Agency as appropriate to meet the 
information requirements under this Regulation. To this end, the Commission, following 
consultation with relevant stakeholders, should propose to amend the future Commission 
Regulation on test methods or this Regulation, where appropriate, t
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animal testing. The Commission and the Agency should ensure that reduction of animal 
testing is a key consideration in the development and maintenance of guidance for 
stakeholders and in the Agency's own procedures.  
 
Recital (49). Sharing of information, in particular to reduce animal testing. In order to 
avoid duplication of work, and in particular to reduce testing involving vertebrate animals, 
the provisions concerning preparation and submission of registrations and updates should 
require sharing of information where this is requested by any registrant. If the information 
concerns vertebrate animals, the registrant should be obliged to request it.  
 
Recital (50). Sharing of information, in particular to reduce animal testing. It is in the 
public interest to ensure the quickest possible circulation of test results on human health or 
environmental hazards of certain substances to those natural or legal persons which use them, 
in order to limit any risks associated with their use. Sharing of information should occur 
where this is requested by any registrant, in particular in the case of information involving 
tests on vertebrate animals, under conditions that ensure a fair compensation for the company 
that has undertaken the tests.  
 
Recital (64). To prevent unnecessary testing, interested parties have 45 days to comment 
on testing proposals. In order to prevent unnecessary animal testing, interested parties 
should have a period of 45 days during which they may provide scientifically valid 
information and studies that address the relevant substance and hazard end-point, which is 
addressed by the testing proposal. The scientifically valid information and studies received by 
the Agency should be taken into account for decisions on testing proposals.  
 
Article 2(4b). Application. (4) REACH regulation shall apply without prejudice to (b) 
Directive 76/768/EEC (cosmetics) as regards testing involving vertebrate animals within the 
scope of that Directive.  
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Article 2(6b). Application. (6) The provisions of Title IV shall not apply to the following 
preparations in the finished state, intended for the final user: (b) cosmetic products as defined 
in Directive 76/768/EEC. 
 
Article 13(1). General requirements for generation of information on intrinsic properties 
of substances. (1) Information on intrinsic properties of substances may be generated by 
means other than tests, provided that the conditions set out in Annex XI are met. In particular 
for human toxicity, information shall be generated whenever possible by means other than 
vertebrate animal tests, through the use of alternative methods, for example, in vitro methods 
or qualitative or quantitative structure-activity relationship models or from information from 
structurally related substances (grouping or read-across). Testing in accordance with Annex 
VIII, Sections 8.6 and 8.7, Annex IX and Annex X may be omitted where justified by 
information on exposure and implemented risk management measures as specified in Annex 
XI, section 3.  
 
Article 13(2). General requirements for generation of information on intrinsic 
properties of substances. (2) These methods shall be regularly reviewed and improved with 
a view to reducing testing on vertebrate animals and the number of animals involved. The 
Commission, following consultation with relevant stakeholders, shall, as soon as possible, 
make a proposal, if appropriate, to amend the Commission Regulation on test methods 
adopted in accordance with the procedure referred to in Article 133(4), and the Annexes of 
this Regulation, if relevant, so as to replace, reduce or refine animal testing. Amendments to 
that Commission Regulation shall be adopted in accordance with the procedure specified in 
paragraph 3 and amendments to the Annexes of this Regulation shall be adopted in 
accordance with the procedure referred to in Article 131.  
 
Article 13(4). General requirements for generation of information on intrinsic properties 
of substances. (4) Ecotoxicological and toxicological tests and analyses shall be carried out 
in compliance with the principles of good laboratory practice provided for in Directive 
2004/10/EC or other international standards recognised as being equivalent by the 
Commission or the Agency and with the provisions of Directive 86/609/EEC, if applicable. 
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Article 14(5b). Chemical safety report and duty to apply and recommend risk reduction 
measures. (5) The chemical safety report need not include consideration of the risks to 
human health from the following end uses: (b) in cosmetic products within the scope of 
Directive 76/768/EEC.  
 
Article 25(1). Objectives and general rules. (1) In order to avoid animal testing, testing on 
vertebrate animals for the purposes of this Regulation shall be undertaken only as a last 
resort. It is also necessary to take measures limiting duplication of other tests.  
 
Article 26(1c). Duty to inquire prior to registration. (1) Every potential registrant of a non-
phase-in substance, or potential registrant of a phase-in substance who has not preregistered 
in accordance with Article 28, shall inquire from the Agency whether a registration has 
already been submitted for the same substance. He shall submit all the following information 
to the Agency with the inquiry: (c) which information requirements would require new 
studies involving vertebrate animals to be carried out by him;  
 
Article 26(3). Duty to inquire prior to registration. (3) If the same substance has previously 
been registered less than 12 years earlier, the Agency shall inform the potential registrant 
without delay of the names and addresses of the previous registrant(s) and of the relevant 
summaries or robust study summaries, as the case may be, already submitted by them. 
Studies involving vertebrate animals shall not be repeated. The Agency shall simultaneously 
inform the previous registrants of the name and address of the potential registrant. The 
available studies shall be shared with the potential registrant in accordance with Article 27.  
 
Article 27(1a). Sharing of existing data in the case of registered substances. (1) Where a 
substance has previously been registered less than 12 years earlier as referred to in Article 
26(3), the potential registrant: (a) shall, in the case of information involving tests on 
vertebrate animals; and (b) may, in the case of information not involving tests on vertebrate 
animals, request from the previous registrant(s) the information he requires with respect to 
Article 10(a)(vi) and (vii) in order to register.  
124 
 
Article 30(1). Sharing of data involving tests. (1) Before testing is carried out in order to 
meet the information requirements for the purposes of registration, a SIEF participant shall 
inquire whether a relevant study is available by communicating within his SIEF. If a relevant 
study involving tests on vertebrate animals is available within the SIEF, a participant of that 
SIEF shall request that study. If a relevant study not involving tests on vertebrate animals is 
available within the SIEF, a SIEF participant may request that study. 
Within one month of the request, the owner of the study shall provide proof of its cost to the 
participant(s) requesting it. The participant(s) and the owner shall make every effort to ensure 
that the costs of sharing the information are determined in a fair, transparent and non 
discriminatory way. This may be facilitated by following any cost sharing guidance which is 
based on those principles and is adopted by the Agency in accordance with Article 77(2)(g). 
If they cannot reach such an agreement, the cost shall be shared equally. The owner shall give 
permission to refer to the full study report for the purpose of registration within two weeks of 
receipt of payment. Registrants are only required to share in the costs of information that they 
are required to submit to satisfy their registration requirements.  
 
Article 30(3). Sharing of data involving tests. (3) If the owner of a study as referred to in 
paragraph 1 which involves testing on vertebrate animals refuses to provide either proof of 
the cost of that study or the study itself to (an) other participant(s), he shall not be able to 
proceed with registration until he provides the information to the other participants(s). The 
other participant(s) shall proceed with registration without fulfilling the relevant information 
requirement, explaining the reason for this in the registration dossier. The study shall not be 
repeated unless within 12 months of the date of registration of the other participant(s), the 
owner of this information has not provided it to them and the Agency decides that the test 
should be repeated by them. However, if a registration containing this information has 
already been submitted by another registrant, the Agency shall give the other participant(s) 
permission to refer to the information in his registration dossier (s). The other registrant shall 
have a claim on the other participant(s) for an equal share of the cost, provided he makes the 
full study report available to the other participant(s), which shall be enforceable in the 
national courts.  
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Article 38(2f). Obligation for downstream users to report information. (2) The information 
reported by the downstream user shall include the following: (f) except where the 
downstream user is relying on the exemption in Article 37(4)(c), a proposal for additional 
testing on vertebrate animals, where this is considered necessary by the downstream user to 
complete his chemical safety assessment.  
 
Article 40(2). Examination of testing proposals. (2) Information relating to testing proposals 
involving tests on vertebrate animals shall be published on the Agency website. The Agency 
shall publish on its website the name of the substance, the hazard end-point for which 
vertebrate testing is proposed, and the date by which any third party information is required. 
It shall invite third parties to submit, using the format provided by the Agency, scientifically 
valid information and studies that address the relevant substance and hazard endpoint, 
addressed by the testing proposal, within 45 days of the date of publication. All such 
scientifically valid information and studies received shall be taken into account by the 
Agency in preparing its decision in accordance with paragraph 3.  
 
Article 56(5a). General provisions. (5) In the case of substances that are subject to 
authorization only because they meet the criteria in Article 57(a), (b) or (c) or because they 
are identified in accordance with Article 57(f) only because of hazards to human health, 
paragraphs 1 and 2 of this Article shall not apply to the following uses: (a) uses in cosmetic 
products within the scope of Directive 76/768/EEC;  
 
Article 67(2). General provisions. (2) Paragraph 1 shall not apply to the use of substances in 
cosmetic products, as defined by Directive 76/768/EEC, with regard to restrictions addressing 
the risks to human health within the scope of that Directive.  
 
Article 117(3). Reporting. (3) Every three years the Agency, in accordance with the 
objective of promoting non-animal testing methods, shall submit to the Commission a report 
on the status of implementation and use of non-animal test methods and testing strategies 
used to generate information on intrinsic properties and for risk assessment to meet the 
requirements of this Regulation. The first report shall be submitted by 1 June 2011.  
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Article 117(4b). Reporting. (4) Every five years, the Commission shall publish a general 
report on: (a) the experience acquired with the operation of this Regulation, including the 
information referred to in paragraphs 1, 2 and 3 and; (b) the amount and distribution of 
funding made available by the Commission for the development and evaluation of alternative 
test methods. The first report shall be published by 1 June 2012.  
 
Article 138(3). Review. (3) The report, referred to in Article 117(4), on the experience 
acquired with the operation of this Regulation shall include a review of the requirements 
relating to registration of substances manufactured or imported only in quantities starting at 
one tonne but less than 10 tonnes per year per manufacturer or importer. On the basis of that 
review, the Commission may present legislative proposals to modify the information 
requirements for substances manufactured or imported in quantities of one tonne or more up 
to 10 tonnes per year per manufacturer or importer, taking into account the latest 
developments, for example in relation to alternative testing and (quantitative) structure- 
activity relationships ((Q)SARs).  
 
Article 138(9). Review. (9) In accordance with the objective of promoting non-animal testing 
and the replacement, reduction or refinement of animal testing required under this 
Regulation, the Commission shall review the testing requirements of Section 8.7 of Annex 
VIII by 1 June 2019. On the basis of this review, while ensuring a high level of protection of 
health and the environment, the Commission may propose an amendment in accordance with 
the procedure referred to in Article 133(4).  
 
Annex I – GENERAL PROVISIONS FOR ASSESSING SUBSTANCES AND 
PREPARING CHEMICAL SAFETY REPORTS.  
4.1. Step 1: Comparison with the Criteria. This part of the PBT and vPvB assessment shall 
entail the comparison of the available information, which is submitted as part of the technical 
dossier, with the criteria given in Annex XIII and a statement of whether the substance fulfils 
or does not fulfil the criteria. 
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If the available information is not sufficient to decide whether the substance fulfils the criteria 
in Annex XIII, then other evidence like monitoring data available for the registrant and 
giving rise to an equivalent level of concern shall be considered on a case-by-case basis. 
If the technical dossier contains for one or more endpoints only information as required in 
Annexes VII and VIII, the registrant shall consider information relevant for screening for P, 
B and T properties to decide whether further information needs to be generated to fulfil the 
objective of the PBT and vPvB assessment. In case the generation of further information is 
necessary and would require testing on vertebrate animals, the registrant shall submit a 
testing proposal. However, such further information does not need to be generated if the 
registrant implements or recommends sufficient risk management measures and operational 
conditions that enable derogation according to Section 3 of Annex XI from testing relevant 
for PBT and vPvB assessment.  
 
Annex VI – INFORMATION REQUIREMENTS REFERRED TO IN ARTICLE 10 
Step 1 - Gather And Share Existing Information. 
The registrant should gather all existing available test data on the substance to be registered, 
this would include a literature search for relevant information on the substance. Wherever 
practicable, registrations should be submitted jointly, in accordance with Articles 11 or 19. 
This will enable test data to be shared, thereby avoiding unnecessary testing and reducing 
costs. The registrant should also collect all other available and relevant information on the 
substance regardless whether testing for a given endpoint is required or not at the specific 
tonnage level. This should include information from alternative sources (e.g. from (Q)SARs, 
read-across from other substances, in vivo and in vitro testing, epidemiological data) which 
may assist in identifying the presence or absence of hazardous properties of the substance and 
which can in certain cases replace the results of animal tests. 
In addition, information on exposure, use and risk management measures in accordance with 
Article 10 and this Annex should be collected. Considering all this information together, the 
registrant will be able to determine the need to generate further information. 
Step 4 - Generate New Data/Propose Testing Strategy. 
In some cases it will not be necessary to generate new data. However, where there is an 
information gap that needs to be filled, new data shall be generated (Annexes VII and VIII), 
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or a testing strategy shall be proposed (Annexes IX and X), depending on the tonnage. New 
tests on vertebrates shall only be conducted or proposed as a last resort when all other data 
sources have been exhausted. 
In some cases, the rules set out in Annexes VII to XI may require certain tests to be 
undertaken earlier than or in addition to the standard requirements.  
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